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REAMBLE
he American College of Cardiology (ACC) and the
merican Heart Association (AHA) recognize the impor-
ance of refining the lexicon used to describe the process and
utcomes of clinical care, whether in randomized trials,
bservational studies, registries, or quality improvement
nitiatives. Broad professional agreement on a common
ocabulary with common definitions will facilitate cross-
tudy comparisons or, when advantageous, combining of
ata across studies and improving the assessment of any
roject’s generalizability to clinical practice. To further
fforts aimed at standardizing such a lexicon, the ACC and
HA have undertaken to develop and publish clinical data
tandards—sets of standardized data elements and corre-
ponding definitions that can be used in a variety of data
ollection efforts for a range of cardiovascular conditions.
It is hoped that these clinical data standards will do the
ollowing:
. improve cross-comparison of results and clinical out-
comes between different trials and registries;
. facilitate the development and conduct of future regis-
tries, at both hospital and national levels, by providing a
list of major variables, outcomes, and definitions;
. facilitate measurement for quality improvement pro-
grams; and
. become the basis for a standardized medical documen-
tation process with the anticipation that the medical
record will progress to an electronic format.
The ACC/AHA Task Force on Clinical Data Standards
akes every effort to avoid any actual or potential conflicts
f interest that may arise as a result of an outside relation-
hip or a personal, professional, or business interest of a
ember of the writing panel. Specifically, all members of
he writing group were required to complete and submit a
isclosure form showing all such relationships that might be
erceived as real or potential conflicts of interest. These
tatements are reviewed by the ACC/AHA Task Force on
linical Data Standards, reported orally to all members of
he writing panel at the first meeting, and updated as thanges occur. Writing Committee members’ relationships
ith industry are listed in Appendix C. Relationships with
ndustry for official peer reviewers are listed in Appendix D.
The ACC/AHA Task Force on Clinical Data Standards
elects cardiovascular conditions and procedures that would
enefit from the creation of a data standard set. Experts in
he subject are selected to examine/consider existing data
tandards and develop a comprehensive, yet not exhaustive,
ata standard set. Users should understand that when
ndertaking a data collection effort, only a subset of the
lements contained in a clinical data standards listing may
e needed or, conversely, they may want to consider
hether it may be necessary to collect some elements not
isted. For example, in the setting of a randomized clinical
rial of a new drug, additional information would likely be
equired regarding study procedures and drug therapies.
The ACC and AHA aim to standardize the language
sed to describe cardiovascular diseases and procedures,
nhance consistency in cardiology, and increase opportuni-
ies for sharing data across various data sources. The
ltimate goal of ACC/AHA clinical data standards is to
ontribute to the infrastructure necessary for accomplishing
he ACC/AHA’s mission of fostering optimal cardiovascu-
ar care and disease prevention.
The ACC and AHA support their members’ goal to
mprove cardiovascular care and disease prevention through
rofessional education, promotion of research, development
f guidelines and standards for cardiovascular care, and
ostering policy that supports optimal patient outcomes.
he ACC and AHA recognize the importance of the use of
linical data for patient management, in the assessment of
atient outcomes, and in research efforts focused on improv-
ng clinical treatment of patients.
As a component of this objective, the ACC/AHA clinical
ata standards concentrate on the identification, definition,
nd standardization of data corresponding with various
linical topics in cardiology. The primary goal of clinical
ata standards is to assist in the collection of data by
roviding an initial platform of data elements and corre-
ponding definitions applicable to various disease conditions
n cardiology. These key elements and definitions are a
ompilation of variables applicable in the measurement of
atient clinical management and outcomes, and for research
nd epidemiological assessments.
The Health Insurance Portability and Accountability Act
HIPAA) privacy regulations, which went into effect in
pril 2003, have heightened all practitioners’ awareness of
ur professional commitment to safeguard our patients’
rivacy. Our goal is to treat every patient’s health informa-
ion with the same respect and courtesy as their person. The
IPAA privacy regulations (http://www.hhs.gov/ocr/
ombinedregtext.pdf, page 31) specify which information
lements are considered “protected health information.”
hese elements may not be disclosed to third parties
including registries and research studies) without the pa-
ient’s written permission. Protected health information
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nder a data use agreement. Research studies using pro-
ected health information must be reviewed by an institu-
ional review board or a privacy board.
We have included identifying information in all clinical
ata standards to facilitate uniform collection of these
lements when appropriate. For example, a longitudinal
linic database may contain these elements, since access is
estricted to the patient’s caregivers. On the other hand,
egistries may not contain protected health information
nless specific permission is granted by each patient. These
elds are indicated as protected health information in the
ata standards.
Our understanding of the importance of data element
tandardization, the backbone of clinical care, clinical re-
earch, and quality performance measurement derives from
xperience with clinical care, clinical research, and quality
erformance measurement. In clinical care, caregivers com-
unicate with each other through a common vocabulary.
he integrity of clinical research depends in large part on
rm adherence to pre-specified procedures for patient en-
ollment and follow-up; these procedures are guaranteed
hrough careful attention to definitions enumerated in the
tudy design and case-report forms. When data elements
nd definitions are standardized across studies, comparison,
ooled analysis, and meta-analysis are enabled, thus deep-
ning our understanding of individual clinical trials.
The recent development of quality performance measure-
ent initiatives, particularly those for which comparison of
roviders is an implicit or explicit aim, has further raised
wareness among the professional community about the
mportance of data standards. For the first time, a wide
udience, including non-medical professionals such as pay-
rs, regulators, and consumers, may draw conclusions about
are and outcomes. For understanding and comparison of care
atterns and outcomes to be fair, the data elements that
ompose the descriptions of these patterns and outcomes of
are must be clearly defined, consistently used, and properly
nterpreted by a broader audience than ever before.
Paul A. Heidenreich, MD, MS, FACC,
Chair, ACC/AHA Task Force on Clinical Data Standards
. INTRODUCTION
he current era of clinical cardiac electrophysiology (EP)
egan in the late 1960s with the introduction and growth of
P laboratories. What began as a diagnostic field focused on
mproving our understanding of cardiac conduction defects,
hen spread into diagnostic studies of patients with tachy-
rrhythmias, both supraventricular and ventricular. This
iscipline has now evolved into one in which therapeutic
entures have displaced diagnosis as the major focus. Ther-
pies directed by electrophysiologists encompass two major
ypes: 1) catheter-based, for cure or palliation of tachyar-
hythmias; and 2) device-based, for both bradyarrhythmias
s well as tachyarrhythmias. More recently, EP has influ- hnced the treatment of patients with heart failure, using
nique pacing modalities. This discipline will continue to
volve, and one can foresee EP catheters and devices being
tilized to deliver novel molecular and genetic therapies in
he future.
Increasing emphasis is being placed on the outcomes of
reatment. If we are to evaluate the results of new, as well as
stablished, treatments, it is necessary to characterize pa-
ients accurately. This, in turn, requires the creation of
atabases that not only record patient attributes, but permit
omparison between patient groups. Description of patient
haracteristics, as well as treatment outcomes, is vital not
nly to researchers, but to practitioners. Every physician
nvolved in patient care is obligated to critically evaluate the
esults of the care they deliver. If we do not question the results
f our interactions with patients, we will perpetuate miscon-
eptions, repeat previous mistakes, and retard the advancement
f medical science. It is in this spirit that we present this first
dition of the ACC/AHA/HRS Electrophysiology Clinical
ata Standards.
It is recognized that cardiac arrhythmias and electro-
hysiologic properties are influenced to a large extent by a
atient’s age. Normal values of electrophysiologic and elec-
rocardiographic parameters for persons under 18 years of
ge differ from those of adults. The electrophysiologic
arameters for persons under age 18 vary and change with
rowth. The normal values provided in this document apply
o persons over age 18. Although certain arrhythmias may
ccur primarily or exclusively in the pediatric or adult
opulations, the committee feels there is merit in providing
ne document, for purposes of continuity and inclusiveness.
n constructing this document we have tried to use terms
eneral enough to make the document useful and appropri-
te for both pediatric and adult electrophysiologists.
This document is meant to serve two major purposes.
he first goal is to serve as the basis for databases employed
n clinical research as well as practice. Our intent was to be
s inclusive as possible. We have tried to provide a compre-
ensive instrument that would prove useful to physicians
nd other professionals involved in the care of patients with
ardiac arrhythmias or implanted rhythm management de-
ices. The intent of this document is not to mandate data to
e collected nor do we expect that all the data elements will
e utilized in every setting. Rather, we expect practitioners
ill pick and choose data elements as appropriate for
ndividual projects.
The second major goal of this project is to provide
tandard definitions of terms relevant to the care of patients
ith arrhythmias and implanted rhythm management de-
ices. We anticipate this will facilitate communication and
romote a common language to foster meaningful compar-
sons and assessment of analyses and outcomes. Some
efinitions are arbitrary because of a lack of sufficient data to
rovide a rational pathophysiologic basis. In such cases, we
ave tried to incorporate common usage, with the expecta-
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hortcomings.
The writing committee anticipates that the EP data
tandards will prove useful in several settings:
Clinical programs, where many providers and health plans
work together to achieve specific goals for the care of
patients with arrhythmias and arrhythmia management
devices. Data standards will assist in the organization and
design of electronic medical information initiatives, such
as electronic medical records, pharmacy and other clinical
databases, or computerized decision support.
Clinical research, including prospective registries and ran-
domized controlled trials (RCTs). Meta-analyses of
RCTs would be particularly strengthened by the use of
standardized data for key variables.
Quality-performance measurement initiatives. Data stan-
dards will especially facilitate interpretation for nonmed-
ical users, such as payors, regulators, and consumers.
I. METHODOLOGY
. Writing Committee Composition
he ACC/AHA Task Force on Clinical Data Standards
elected members for the ACC/AHA/HRS Writing Com-
ittee to Develop Clinical Data Standards for Electrophys-
ology. The committee consisted of 14 members who are
ctive in clinical research in adult EP, as well as heart failure
nd general cardiology. The committee included member-
hip from across the U.S., so as to ensure balance in the
election of data elements and consideration of variations in
ractice. To ensure consistency between the clinical data
tandards and other ACC/AHA/HRS standards, the Task
orce appointed representatives who had served on other
CC/AHA Guideline Writing Committees.
. Review of Literature and Existing Data Definitions
he ACC/AHA/HRS Task Force on Clinical Data Stan-
ards supported gathering as many candidate data elements
nd definitions as possible, principally from large clinical
rials and registries, such as MUSTT (Multicenter Unsus-
ained Tachycardia Trial) (1) and COMPANION (Com-
arison of Medical Therapy, Pacing, and Defibrillation in
eart Failure) (2). The Writing Committee compiled and
eviewed case report forms, data elements, and definitions
rom national, international, and local cardiovascular data
ollection efforts. Examples of these data sources include the
CC National Cardiovascular Data Registry (NCDR)
http://www.accncdr.com/WebNCDR/Common/) and the
CC Key Data Elements and Definitions for Measuring
he Clinical Management and Outcomes of Patients With
cute Coronary Syndromes (3). We also reviewed the
CC/AHA Clinical Data Standards on Heart Failure (4)
nd the ACC/AHA Clinical Data Standards on Atrial
ibrillation (5), as well as the ACC/AHA/ESC Atrial
ibrillation Guidelines (6). bThe EP data standards are meant to provide data ele-
ents that parallel and complement other ACC and AHA
tandards, specifically the guidelines and the performance
easures. These data were developed simultaneously with
ther data standards. Research articles, clinical trials, and
eference sources were consulted as needed and are cited
hroughout this document.
. Defining Data Elements
embers of the Writing Committee drafted definitions.
riters were encouraged to write definitions broad enough
o be applicable in a variety of data collection settings, but
pecific enough that the data elements can be uniformly
nterpreted. In addition, the committee compiled a dictio-
ary of common definitions for arrhythmias mentioned
hroughout this document (see Appendix A) to further
upplement and support consistency in data collection of the
lements and definitions contained in the main document.
ata definitions were linked whenever possible to the
vidence-based national guidelines. To ensure consistency
cross ACC/AHA clinical data standards, writers used an
xisting ACC/AHA definition verbatim unless there was a
eason related to EP to change that definition.
. Relation to Other Data Standards
his committee has reviewed the ACC/AHA Key Data
lements and Definitions for Measuring the Clinical Man-
gement and Outcomes of Patients With Atrial Fibrillation
5). That document addresses certain aspects of data collec-
ion in patients with atrial fibrillation in more detail than is
overed in this document. The committee anticipates that
or certain purposes, use of that document is more appro-
riate.
In an effort to maintain consistency of definitions across
he data standards documents, the committee also reviewed
he ACC Key Data Elements and Definitions for Measur-
ng the Clinical Management and Outcomes of Patients
ith Acute Coronary Syndromes (3) and the ACC/AHA
ey Data Elements and Definitions for Measuring the
linical Management and Outcomes of Adults With
hronic Heart Failure (4).
. Consensus Development
he ACC/AHA data standards are consensus, team-
ritten documents that are based on judgments of experts in
he field of cardiology. This Writing Committee met several
imes, both in person and through conference calls, over the
ourse of several months to define and refine the data
lements. Throughout the creation of the data element set,
onsensus was developed through discussions (either during
ace-to-face meetings or conference calls), e-mails, and
ometimes written votes.
. Peer Review, Public Comment, and Board Approval
he set of EP data elements was independently reviewed
y official reviewers nominated by the ACC, the AHA,
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CC/AHA Task Force on Clinical Data Standards and
ndependent content reviewers. To increase its applica-
ility further, this document was posted on the ACC
eb site (www.acc.org) for a 30-day public comment
eriod from March 23 through April 21, 2005. This
ocument was approved for publication by the governing
odies of the ACC, the AHA, and the HRS.
The Writing Committee anticipates these data standards
ill require regular review and updating, just as is the case
ith guidelines and performance measures. At the anniver-
ary of the data standards publication, the Writing Com-
ittee chair, in conjunction with the Writing Committee
embers, will review the data standards to ascertain
hether or not modifications should be considered. To keep
urrent, whenever a relevant guideline is updated the asso-
iated data standards will be reviewed and updated to reflectII. ELECTROPHYSIOLOGY CLINICAL DATA
TANDARDS ELEMENTS AND DEFINITIONS
. Patient Demographics
atient demographic information is used for patient identifi-
ation for longitudinal care, for demographic grouping to
ssess issues of access and care quality for traditionally disad-
antaged groups, and for risk adjustment. Association of any
ealth information with unique patient identifiers and/or
emographic information that can be linked to the individual
atient (indicated by an asterisk) identifies the dataset as
protected health information.” Unique patient identification
nformation (Social Security number or medical record num-
er) is necessary and appropriate for longitudinal clinical care,
ut given current legislation protecting patients’ privacy (7), is
ot included in multi-institution registries unless appropriate
nformed consent is obtained from all patients. For other uses,
atient privacy concerns may need to be considered by hospitalhose changes. privacy officers and/or institutional review board.
DATA ELEMENT DEFINITION
Date of birth Patient date of birth (day, month, and year of patient’s birth)
Gender Indicate the patient’s gender at birth. Choose one of the following:
● Male
● Female
Race Patient’s race as determined by the patient/family.
● American Indian or Alaska Native
● Asian
● Black or African American
● Native Hawaiian or Other Pacific Islander
● White
● Multi-racial
● Other
Hispanic ethnicity As determined by the patient and/or family, is the patient’s ethnicity Hispanic?
nsurance payor Indicate the patient’s primary insurance payor for this admission. Choose one of the following:
● Government: Refers to patients who are covered by government-reimbursed care. In the U.S., this includes:
— Medicare
— Medicaid (including all state or federal Medicaid-type programs)
— Champus
— Veteran’s Health Affairs
— Department of Defense
— Other federal group (specify)
● Commercial: Refers to all indemnity (fee-for-service) carriers and Preferred Provider Organizations (PPOs).
● HMO: Refers to a Health Maintenance Organization characterized by coverage that provides health care services for
members on a pre-paid basis.
● None: Refers to individuals with no or limited health insurance; thus, the individual is the payor regardless of ability to
pay. Only mark “None” when “self” or “none” is denoted as the first insurance in the medical record.
overnment payor type If the patient’s primary insurance payor for this encounter is “Government,” choose the type of government insurance:
● Medicare
● Medicaid
● Other
resentation to health
care facility
Type of presentation to healthcare facility:
● Emergency admission for documented or suspected arrhythmia
● Emergency admission for heart failure (HF)
● Emergency admission for other cardiovascular problem
● Emergency admission for non-cardiovascular problem (e.g., pneumonia)
● Planned admission for management of documented or suspected arrhythmia
● Planned admission for cardiovascular disease
● Planned admission for non-cardiovascular disease
● Regularly scheduled outpatient visit
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resentation to health
care facility
(continued)
● Other outpatient visits, including urgent outpatient visits
● Remote monitoring
● Telephone contact
● Electronic communication
● Other (specify)
Note if patient is a new patient or a prior patient with a new entry.
utpatient Was procedure done as outpatient?
npatient ● Hospital admission date
● Hospital discharge date
isposition after health
care encounter
Indicate disposition after healthcare encounter:
● Discharged to home or self care (routine discharge)
● Discharged/transferred to another short-term general hospital for inpatient care
● Discharged/transferred to skilled nursing facility
● Discharged/transferred to an intermediate care facility
● Discharged/transferred to another type of institution
● Discharged/transferred to home under care of organized home health service organization
● Left against medical advice or discontinued care
● Discharged/transferred to home under care of a home intravenous drug therapy provider
● Admitted as an inpatient to this hospital
● Expired (or did not recover)
● Hospice—home
● Hospice—medical facility
● Discharged/transferred to an inpatient rehabilitation facility including rehabilitation in distinct part units of a
hospital.
Specify date.
ate of EP study Indicate the date of EP study and/or device-related procedure.Unique patient identifier.
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a. Patient History
nformation about patients’ medical history is important in
uality performance measurement, clinical research, and clin-
cal care. The frequency, severity, and duration of symptoms
ssociated with arrhythmias are of prime importance in deter-
ining appropriate therapy. History of non-cardiac conditions
ay denote absolute or relative contraindications to various
herapies and may significantly impact outcome and prognosis.
nclusion of data elements pertinent to patient history is
herefore important to clinical decision-making, to design of
uality performance measures, and to risk-adjusted outcomes
ssessment. For most purposes, these data elements can be
ecorded as either present or absent. Year of onset may be
elpful, especially when data collection is used for longitudinal
linical follow-up. More detailed information about severity of
ach condition (e.g., record of prior hospitalizations or specifics
f therapy for the condition) might be considered for certainIn addition to general non-cardiac and cardiac history we
ave included space to record detailed history of arrhyth-
ias. Previously documented arrhythmias may be important
or determination of appropriate therapy, as well as carrying
rognostic information. Knowledge of medications being
aken at the time of spontaneous arrhythmia occurrence is
mportant for several reasons:
Medications may facilitate occurrence of arrhythmias, in
association with QT prolongation, as well as re-entrant
arrhythmias not related to QT prolongation.
Medications may alter the clinical manifestations of
arrhythmias, for example by slowing tachycardias, or by
worsening atrioventricular or intraventricular conduction.
ther factors may be important to document, such as the
tandard electrocardiogram (ECG), both in sinus rhythm,
s well as during tachycardias. The standard ECG maysers. provide critical prognostic as well as diagnostic information.
DATA ELEMENT DEFINITION
. Presentations Associated With Arrhythmia
o symptoms The absence of symptoms that could result from an arrhythmia
alpitations Patient reports palpitations, felt either in the chest, throat, or neck, as described by the following:
● Heartbeat sensations that feel like pounding or racing
● An unpleasant awareness of heartbeat
● Feeling skipped beats or a pause
● Provide date of first documented episode of palpitations
● Specify number of episodes. If multiple episodes have occurred, provide frequency.Continued on next page
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resyncope/near syncope Patient reports presyncope/near syncope as described by the following:
● Dizziness
● Lightheadedness
● Feeling faint
● “Graying out”
● Provide date of first documented isode of presyncope/near syncope.
● Specify number of episodes. If multiple episodes have occurred, provide frequency.
yncope Sudden loss of consciousness with loss of postural tone, not related to anesthesia, with spontaneous
recovery as reported by patient or observer. Patient may experience syncope when supine.
● Provide date of first documented episode of syncope.
● Specify number of episodes. If multiple episodes have occurred, provide frequency.
Drop attack” Abrupt loss of postural tone (collapse) without reported loss of consciousness.
● Provide date of first documented episode of “drop attack.”
● Specify number of episodes. If multiple episodes have occurred, provide frequency.
ngina due to arrhythmia History of angina before the current admission. “Angina” refers to evidence or knowledge of symptoms
before this acute event described as chest pain or pressure, jaw pain, arm pain, or other equivalent
discomfort suggestive of cardiac ischemia.
Date of most recent episode may be helpful.
yspnea Patient experiences frequent uncomfortable awareness of breathing in one or both of the following
circumstances (specify):
● Resting in a sitting position
● Exerting him/herself
Year of onset may be helpful.
atigue Patient describes history of unusual tiredness and inability to perform usual activities.
Year of onset may be helpful.
F caused by arrhythmia There are two common situations in which arrhythmias cause HF symptoms:
1. An acute arrhythmia may precipitate acute HF, most often with acute pulmonary edema.
2. A persistent arrhythmia may precipitate symptoms of chronic HF, with a more varied presentation.
ardiac arrest due to arrhythmia “[Sudden] cardiac arrest is the sudden cessation of cardiac activity so that the victim becomes unresponsive,
with no normal breathing and no signs of circulation. If corrective measures are not taken rapidly, this
condition progresses to sudden death. Cardiac arrest should be used to signify an event as described
above, that is reversed, usually by CPR and/or defibrillation or cardioversion, or cardiac pacing. Sudden
cardiac death should not be used to describe events that are not fatal.”
Specify whether cardiac arrest occurred out-of-hospital or in-hospital.
. Arrhythmia History (see Appendix A for a supplemental dictionary of arrhythmia terms used throughout this section)
uration and frequency of arrhythmia For each arrhythmia, provide the following information:
● Provide date of first documented arrhythmia(s)
● Specify number of episodes. If multiple episodes have occurred, provide frequency.
inus node function Indicate the patient’s medical history with respect to sinus node function.
● Normal sinus rhythm (60 to 100 bpm and the cycle length does not vary by more than 10% or
120 ms)
● Sinus arrhythmia
● Wandering atrial pacemaker
● Sinus bradycardia
● Sinoatrial exit block
— Mobitz I
— Mobitz II
● Sinus arrest/pause
● Sinus node dysfunction (bradycardia)
● Sick sinus syndrome
● Sinus node dysfunction following cardiac surgery (transient or permanent)
● Ectopic atrial rhythm
● Other (specify)
Specify date of first documented arrhythmia, number of episodes, and frequency.
trioventricular (AV) conduction Indicate the patient’s medical history with respect to AV conduction.
● Normal AV conduction (PR interval 120 to 200 ms without pre-excitation, bundle branch, or
fascicular block)
● Short PR interval
● PR prolongation (first-degree AV block)
● Second-degree AV block
— Mobitz I
— Mobitz II
● Advanced or high-degree AV block
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trioventricular (AV) conduction
(continued)
● Third-degree AV block (complete heart block)
● AV conduction abnormality following cardiac surgery (transient or permanent)
● Congenital complete heart block
● Isorhythmic dissociation
● Paroxysmal AV block
● Pre-excitation (Delta wave)
● Other (specify)
Specify date of first documented arrhythmia, number of episodes, and frequency.
ntraventricular conduction Indicate the patient’s medical history with respect to intraventricular conduction.
● Normal (no history of intraventricular conduction)
● Left anterior fascicular block
● Left posterior fascicular block
● Left bundle-branch block (LBBB)
● Right bundle-branch block (RBBB)
● Incomplete RBBB
● Intraventricular conduction delay (IVCD), nonspecific
● Intraventricular conduction abnormality following cardiac surgery (transient or permanent)
● Other (specify)
Specify date of first documented arrhythmia, number of episodes, and frequency.
upraventricular tachycardias (SVT) Indicate the patient’s medical history with respect to SVT.
● Normal (no history of SVT)
● SVT
— Recurrent: more than one episode of tachycardia
— Persistent: episodes of tachycardia that require medical intervention (pharmacologic therapy, pacing,
ablation, or cardioversion) for termination
— Paroxysmal: episodes of tachycardia that terminate spontaneously
— Incessant: episodes of tachycardia that resume immediately after termination
● Atrial premature complexes (APC)
● Atrial tachycardia (AT)
— Focal ATs
— Multifocal ATs
● Atrial fibrillation (AF)
— Initial episode of AF
— Paroxysmal AF
— Persistent AF
— Permanent AF
● Macro re-entrant AT
— Cavotricuspid isthmus (CTI)-dependent AF (also typical or type I AF)
— Non–CTI-dependent AF
● Macro–re-entrant AT related to previous cardiac surgery
● Sinus tachycardia (ST)
● Inappropriate ST
— Persistent
— Intermittent/paroxysmal
● Postural orthostatic tachycardia syndrome (POTS)
● AV node re-entry
— Slow-fast
— Fast-slow
— Slow-slow
● Junctional tachycardia
— Congenital junctional ectopic tachycardia (JET)
— Postoperative junctional tachycardia
— Focal junctional tachycardia
— Non-paroxysmal junctional tachycardia (permanent form of junctional tachycardia [PJRT]) AV
re-entrant tachycardia (concealed bypass tract)
● Wolff-Parkinson-White (WPW) syndrome
● Other (specify)
Specify date of first documented arrhythmia, number of episodes, and frequency.
entricular tachycardias (VT) Indicate the patient’s medical history with respect to VT.
● Normal (no history of VT)
Continued on next page
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entricular tachycardias (VT)
(continued)
● VT
— Spontaneous
— Induced
— Sustained
— Nonsustained/unsustained
— Bidirectional
— Exercise-induced
— Narrow complex VT, monomorphic
— Sustained
— Nonsustained/unsustained
— Repetitive
● VT, polymorphic
— Sustained
— Nonsustained/unsustained
— Catecholaminergic
● Premature ventricular complexes (PVC)
● Ventricular couplet
● Accelerated idioventricular rhythm
● VT storm
● Scar-based VT due to prior cardiac surgery
● Adenosine-sensitive VT
● Verapamil-sensitive VT
● Ventricular flutter
● Ventricular fibrillation (VF)
● Torsades de pointes
● Ventricular arrhythmias associated with long QT syndrome
— Congenital
— Acquired (specify heart block, medication, or other)
● Ventricular arrhythmias associated with Brugada syndrome
● Ventricular arrhythmias associated with short QT syndrome
— QTc 300 ms
— History of familial sudden death
— Short refractory periods
— Inducible VF
● Fascicular tachycardia
● Bundle branch re-entrant tachycardia
● Idiopathic RBBB VT
● Outflow tract VT
— Right ventricular
— Left ventricular
● Other (specify)
Specify date of first documented arrhythmia, number of episodes, and frequency.
. History of Medication at Time of Arrhythmia
ntiarrhythmic agents Indicate if patient taking antiarrhythmic agent(s) (including digitalis, beta-adrenergic blocking agents,
or calcium channel blockers) at time of arrhythmia. Specify drug(s).
on-antiarrhythmic cardiovascular
agents
Indicate if patient taking non-antiarrhythmic cardiovascular agent(s) at time of arrhythmia. Specify
drug(s).
on-cardiovascular drugs Indicate if patient taking non-cardiovascular drug(s) at time of arrhythmia. Specify drug(s).
. Specific ECG Patterns
imultaneous ECG leads Multiple ECG lead recordings performed at the same time; indicate number of simultaneous ECG
leads recorded.
-wave duration Time required for complete depolarization of both right and left atria. Duration of P-wave in milliseconds,
measured from at least 3 simultaneous ECG leads, preferably including leads I, II, and V1.
R interval Longest measured time from onset of P wave to onset of QRS complex in any given ECG lead.
RS duration Time required for complete depolarization of the right and left ventricles, measured in milliseconds
from simultaneous (preferably 3 or more) ECG leads, including I, II, and V1, from the onset to the
termination of the QRS.
psilon wave Delayed ventricular depolarization wave, usually seen in the early precordial leads (V1 thorough V3) as a
notch or fragmented potential at the end of the QRS or early during the ST-segment. It signifies
delayed (slowed or fractionated) ventricular depolarization (in the right ventricle and seen with right
ventricular cardiomyopathy [arrhythmogenic right ventricular dysplasia or cardiomyopathy]). It
correlates with the late potentials seen on the signal-averaged ECG, and it has also been called a
“ventricular post-excitation wave.”
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istory of prolonged QT interval History of ECG findings of prolonged QT interval.
ong QT Prolongation of the corrected QT interval (QTc) beyond 440 ms for adult males, 460 ms for adult
females, and 500 ms in the presence of ventricular depolarization abnormalities (i.e., bundle branch
blocks or IVCDs more than 120 ms.
. History of Previous Therapeutic Strategies
reviously used therapeutic
strategies for AF
Indicate the types of therapeutic strategies that have been used previously.
Rate control:
● Pharmacologic (specify individual drugs used)
● Nonpharmacologic
— Ablation of AV junction with implantation of pacemaker
— Modification of AV node function
● Hybrid*
● None
Rhythm control:
● Pharmacologic (specify individual drugs used)
● Nonpharmacologic
— Pulmonary vein (PV) focus
— Segmental PV isolation
— Ostial PV isolation
— Extra-ostial PV isolation
— Linear ablation
— Substrate modification
— AV junction ablation
— AV junction modification
● Specify energy source used for ablation
— Radiofrequency
— Cryo-ablation
— Ultrasound
● Hybrid*
● None
*Hybrid is defined as concurrent use of:
● Pharmacologic and nonpharmacologic therapies or
● Two or more nonpharmacologic therapies
reviously used therapeutic strategies for
other arrhythmias
Indicate the types of therapeutic strategies that have been used previously.
Pharmacologic:
—Indicate number of drug trials
—Indicate drugs tried
Device:
—Device type (specify—See “History of pacemaker insertion” and “History of ICD insertion”)
Ablation:
—Number of ablation procedures
—Ablation target(s)
—Energy source(s)—radiofrequency, cryo, utrasound
Hybrid therapy (combination of 2 or more of pharmacologic, device, or ablation)
No previous therapy
. Pacemaker/Implantable Cardioverter-Defibrillator (ICD) History
istory of pacemaker insertion Indicate if the patient has had a pacemaker inserted. If yes, specify type:
● Single chamber (atrial)
● Single chamber (ventricular)
● Dual chamber (both atrial and ventricular)
● Biventricular of any type (specify)
Specify indication (all that apply):
● Sinus node dysfunction
● AV block
● AF
● Neurocardiogenic syncope (carotid sinus hypersensitivity and vasovagal syncope)
● Hypertrophic cardiomyopathy
● Medically refractory HF
● SVT (historically)
● Other (specify)
Venous access:
● Subclavian
● Axillary
Continued on next page
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istory of pacemaker insertion
(continued)
● Internal jugular
● External jugular
● Cephalic
● Femoral
Lead positions:
● Atrial:
— Right atrial appendage
— Right atrial free wall
— Right atrial septum
— Adjacent to coronary sinus ostium
● Ventricular:
— Right ventricular apex
— Right ventricular inflow
— Right ventricular outflow
● Epicardial
● Subcutaneous array
Coronary sinus:
● Tributaries that allow atrial stimulation
● Tributaries that allow ventricular stimulation
Specify if capable of:
● Burst pacing
● Anti-tachycardia pacing
Specify date of current implant. Specify manufacturer and model number.
urrent pacing mode Indicate the current pacing mode (8):
● VVI
● VVIR
● DDD
● DDDR
● DDI
● DDIR
● AAI
● AAIR
● VDD
● VDDR
● DVI
● DVIR
● VOO
● DOO
● VOOR
● DOOR
● AOOR
● Other (specify)
istory of ICD insertion Indicate if the patient has or has had an ICD inserted. If yes, specify type:
● Single chamber
● Dual chamber
● Biventricular
Specify indication:
● AF
● Secondary prevention of cardiac arrest
● Primary prevention of cardiac arrest
● High risk for VT (e.g., ischemic heart disease, hypertrophic cardiomyopathy, Brugada syndrome, long
QT syndrome, HF)
● Syncope with inducible VT
Specify if capability exists:
● Burst pacing
● Anti-tachycardia pacing
● Cardioversion
urrent ICD Mode ● VVEV
● VVED
● DDED
● AAEV
● DDHD
● Other (specify ICD mode as programmed)
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. Other Cardiovascular History
istory of symptoms representative of
angina
Previous angina may include:
● Stable angina
● Unstable angina
Dates should be sought for the onset of either stable or unstable angina.
istory of HF Physician documentation or report of any of the following symptoms of HF prior to this care encounter
described as dyspnea, fluid retention, or low cardiac output secondary to cardiac dysfunction; or the
description of rales, jugular venous distension, or pulmonary edema. A previous hospital admission
with principal diagnosis of HF is considered evidence of HF history.
F status (NYHA functional
classification)
New York Heart Association (NYHA) functional class as reported by a physician:
● Class I: Patients with cardiac disease but without resulting limitations of physical activity. Ordinary
physical activity does not cause undue fatigue, palpitation, or dyspnea.
● Class II: Patients with cardiac disease resulting in slight limitation of physical activity. They are
comfortable at rest. Ordinary physical activity results in fatigue, palpitation, or dyspnea.
● Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are
comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
● Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without
discomfort. Symptoms are present even at rest or minimal exertion.
F stage ● A  Patient at high risk for developing HF but who has no structural disorder of the heart.
● B  Patient with a structural disorder of the heart but who has never developed symptoms of HF.
● C  Patient with past or current symptoms of HF associated with structural heart disease.
● D  Patient with end-stage disease who requires specialized treatment strategies such as mechanical
circulatory support, continuous inotropic infusions, cardiac transplantation, or hospice care.
vidence for ischemic heart disease Any of the following conditions indicates ischemic heart disease:
● At least one major epicardial coronary artery with more than 70% obstruction by coronary
angiography.
● History of acute myocardial infarction associated with wall motion abnormality by echocardiography
or gated blood pool imaging.
● Stress testing (with or without imaging) diagnostic of coronary artery disease.
istory of myocardial infarction Previous myocardial infarction prior to this encounter as determined by the following (indicate all that
apply):
● Hospital admission for acute myocardial infarction
● ECG report indicating previous (old) or acute myocardial infarction
● Increase in biochemical marker (creatine kinase or troponin) consistent with myocardial infarction
● Patient reports history of acute myocardial infarction or heart attack
Date of the first and the most recent episode may be helpful.
istory of hypertension Indicate if the patient has hypertension as documented by:
● History of hypertension diagnosed and treated with medication, diet, and/or exercise.
● Blood pressure 140 mm Hg systolic or 90 mm Hg diastolic on at least 2 occasions.
● Blood pressure 130 mm Hg systolic or 80 mm Hg diastolic on at least 2 occasions for patients with
diabetes or chronic kidney disease (9).
More than one of the above may apply. The year of onset (first diagnosis) may be helpful.
vidence for hypertensive
cardiomyopathy
One of the following conditions must be met:
● Untreated systolic blood pressure 160 mm Hg or diastolic 105 mm Hg for at least 3 months.
● Hypertension requiring at lest 2 drugs for control for at least 5 years.
● Presence of diabetes and hypertension, treated or untreated.
● Documented left ventricular hypertrophy (preferably by echocardiography or magnetic resonance
imaging [MRI]).
● Absence of other etiologies for HF.
istory of congenital heart disease Patient has documented history of congenital heart disease confirmed by echocardiography, computed
tomography, MRI, or catheterization.
Specify type of lesion or types of lesions, specify surgical repair or percutaneous intervention, and date(s).
vidence for myocardial infiltrative or
storage disease
● Systemic amyloidosis by biopsy.
● Hemochromatosis by biopsy or by serum markers in the presence of clinical evidence of multi-organ
involvement.
vidence for myocardial infiltrative or
storage disease (continued)
● Sarcoidosis with clinical or biopsy evidence for multi-organ involvement and reduced left ventricular
systolic function.
● HF in a patient with a storage disease known to involve the myocardium, including Fabry disease,
Gaucher disease, or the glycogen storage diseases.
● Other (specify)
Continued on next page
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vidence for toxic cardiomyopathy ● Alcohol abuse present for at least 5 years as defined by either heavy alcohol consumption (i.e.,
75 g/day at least 5 days/week) or alcohol dependence (i.e., American Psychiatric Association’s
DSM-IV definition).
● Cocaine use.
● Temporally related exposure to a drug or substance known to cause cardiomyopathy, including
chemotherapeutic agents(s) and radiation to the chest.
● Other (specify)
vidence for inflammatory myocarditis ● Biopsy-proven myocarditis.
● Chagas disease by serologic tests for T. cruzi infection
● Sarcoidosis with biopsy evidence or diagnostic pulmonary radiographic appearance with reduced left
ventricular systolic function.
● Other (specify)
vidence for valvular heart disease Primary valvular disease:
● Moderately severe or severe, or 3 or 4 aortic insufficiency.
● Moderately severe or severe, or 3 or 4 mitral insufficiency with echocardiographic evidence that
mitral insufficiency is a primary abnormality and not secondary to ventricular dilation.
● Moderately severe or severe aortic stenosis defined by estimated aortic valve area by catheterization or
Doppler echocardiography of 1.0 cm2.
● Moderately severe or severe mitral stenosis defined by estimated mitral valve area by catheterization or
echocardiography of 1.0 cm2.
● Other (specify pulmonic or tricuspid disease)
Contributory valvular disease:
● Valve disease that is felt to be significant but does not fulfill the aforementioned definitions.
vidence for ventricular dysfunction due
to tachyarrhythmias
HF attributed to sustained (usually 1 week) tachycardia (usually more than 120 bpm, cycle length
500 ms) that is not attributable to any other cause and shows evidence for improvement after
correction of tachycardia.
vidence for primary myocardial
hypertrophic or other muscle disease
● Evidence of hypertrophy by echocardiography or MRI not attributable to hypertension
— Specify: symmetric, asymmetric, or apical
— Specify: obstructive or nonobstructive
● Congenital muscular dystrophy
● Other (specify)
rrhythmogenic right ventricular
dysplasia/cardiomyopathy (ARVD/C)
Inherited cardiomyopathy characterized by ventricular arrhythmia and right ventricular dysfunction (10).
vidence for idiopathic cardiomyopathy HF and reduced systolic function without evidence for any of the aforementioned etiologies or other
disease known to cause cardiomyopathy.
. History of Invasive Cardiac Interventions/Surgery
istory of percutaneous coronary
revascularization procedure
Previous percutaneous coronary intervention of any type (balloon angioplasty, atherectomy, stent, or other),
done prior to the current encounter.
Date of most recent intervention may be helpful.
istory of coronary artery bypass graft
(CABG) surgery
CABG prior to the current encounter.
Year of most recent intervention may be helpful.
istory of other cardiac surgery Indicate if patient has a history of other cardiac surgery. Specify type of surgery and date performed.
istory of intervention for congenital
heart disease
Indicate if patient has a history of intervention for congenital heart disease.
Specify defect:
● Atrial septal defect, ventricular septal defect, patent ductus arteriosus, artrioventricular septal defect
● Tetralogy of Fallot; D and L transportation of the great arteries, Ebstein’s anomaly, functional single
ventricle
● Aortic, mitral, and pulmonary stenosis
● Persistent left superior vena cava
● Other (specify)
Date of intervention may be helpful.
istory of valve intervention Indicate each valve repair, valvuloplasty, or valve replacement in patient history. Indicate location, type,
and date of intervention.
. Non-Cardiovascular History
istory of diabetes mellitus Indicate if patient has a history of diabetes, regardless of duration of disease, need for antidiabetic agents,
or a fasting blood sugar 7 mmol/l or 126 mg/dl. Indicate if currently taking insulin.
The year of onset (first diagnosis) may be helpful.
istory of chronic liver disease Indicate if patient has a history of documented cirrhosis or chronic liver disease.
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istory of cerebrovascular disease Indicate if the patient has a history of cerebrovascular disease, documented by any one of the following:
● Cerebrovascular accident (CVA): patient has a history of stroke (i.e., loss of neurological function with
residual symptoms at least 72 h after onset).
● Reversible ischemic neurological deficit (RIND): patient has a history of loss of neurological function
with symptoms at least 24 h after onset but with complete return of function within 72 h.
● Transient ischemic attack (TIA): patient has a history of loss of neurological function that was abrupt
in onset but with complete return of function within 24 h.
● Noninvasive/invasive carotid test with 75% occlusion.
● Previous carotid artery surgery.
istory of peripheral vascular/arterial
disease
Peripheral arterial disease can include the following:
● Claudication, either with exertion or at rest.
● Amputation for arterial vascular insufficiency.
● Vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities.
● Documented aortic aneurysm.
● Positive noninvasive test (e.g., ankle brachial index 0.8).
istory of pulmonary hypertension A mean pulmonary artery pressure 25 mm Hg measured at rest by right-heart catheterization.
Specify primary or secondary.
istory of chronic renal insufficiency Patient has reduced glomerular filtration rate (GFR) for at least 3 months. Degree of renal insufficiency may
be further defined according to degree of depression in GFR:
● Mild renal insufficiency: GFR 60 to 89 ml/min/1.73 m2.
● Moderate renal insufficiency: GFR 30 to 59 ml/min/1.73 m2.
● Severe renal insufficiency: GFR 15 to 29 ml/min/1.73 m2.
● Renal failure: GFR 15 ml/min/1.73 m2, or patient requires chronic dialysis treatment.
Note: GFR may be estimated using the serum creatinine  GFR  186  (PCr)
1.154  (age)0.203 
(0.742 if female)  (1.210 if black).
Year of onset (first diagnosis) may be helpful.
istory of dyslipidemia Indicate if the patient has a history of dyslipidemia diagnosed and/or treated by a physician or other
provider. Criteria can include documentation of:
● Total cholesterol 200 mg/dl, or
● Low-density lipoprotein (LDL) 130 mg/dl, or
● High-density lipoprotein (HDL) 35 mg/dl, or
● Lipid-lowering therapy initiated.
● Hypertriglyceridemia
istory of sleep apnea Indicate if patient has a history of sleep apnea as defined below:
● Obstructive sleep apnea: recurrent collapse of the pharynx during sleep
● Central sleep apnea: transient cessation of neural drive to respiratory muscles
● Mixed
istory of lung disease Documented history of chronic lung disease (e.g., chronic obstructive pulmonary disease, chronic
bronchitis) or currently being chronically treated with inhaled or oral pharmacological therapy (e.g.,
beta-adrenergic agonist, anti-inflammatory agent, leukotriene receptor antagonist, or steroid).
Year of onset (first diagnosis) may be helpful.
istory of musculo-skeletal disease Documented history of primary musculo-skeletal disease, including muscular dystrophy, myasthenia
gravis, dermatomyositis, or myotonic dystrophy.
istory of allergies to medications Significant side effect attributed to drug and requiring permanent discontinuation of drug. List drug
and significant side effect. Record date first noted.
0. Family History
amily history of arrhythmias Family history of early onset of atrial or ventricular arrhythmias or conduction system disease preceding or
unassociated with structural heart disease.
Specific arrhythmia(s) or conduction problem(s) should be stated.
amily history of recurrent syncope Family history of recurrent syncope.
pecific familial arrhythmia syndromes Indicate if patient has a family history of arrhythmia syndromes, such as long QT syndrome, Brugada,
and so on. Specify genotype, if known.
amily history of sudden cardiac death Family history (parent or sibling) of sudden cardiac death, defined as natural death due to cardiac
causes, heralded by abrupt loss of consciousness, occurring before 75 years of age. The time and
mode of death are unexpected even though preexisting heart disease may have been known to be
present. Traumatic death subsequently proven to be due to sudden loss of control due to a cardiac
problem is included.
amily history of ischemic heart disease Any direct blood relatives (parents, siblings, children) with coronary artery disease (defined below)
before age 55 for men and 65 years for women:
● Angina
● Myocardial infarction
Continued on next page
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amilial cardiomyopathy ● Possible familial cardiomyopathy: presence of otherwise unexplained cardiomegaly, diagnosis of HF,
AF or life-threatening ventricular arrhythmias, conduction system disease, or sudden death in first-
degree relative under 60 years of age.
● Probable familial cardiomyopathy: presence of aforementioned in two relatives under 60 years of age
who are related to each other and the patient.. Physical Examination
DATA ELEMENT DEFINITION
eight Patient’s height in centimeters or inches
eight Patient’s weight in kilograms or pounds.
eart rate Heart rate (bpm) recorded closest to the time of presentation to the health care facility and/or on discharge
(for inpatient).
Heart rate may be ascertained from electrocardiographic tracing or from record of physical examination.
ystolic and diastolic blood pressure Systolic and diastolic blood pressure (mm Hg) recorded closest to the time of presentation to the health
care facility. Patient position (supine, sitting, other) should be noted.
hird heart sound (S3) Presence or absence of a third (mid-diastolic) heart sound.
ourth heart sound (S4) Presence or absence of a fourth (late-diastolic) heart sound.
eart murmur Presence or absence of heart murmur(s). Timing (systolic, diastolic), quality (harsh, blowing, ejection,
etc.), and intensity of each murmur should be noted. Intensity is usually graded on a 1 to 6 scale for
systolic murmurs and a 1 to 4 scale for diastolic murmurs.
ung (pulmonary) examination Lung (pulmonary) findings by auscultation:
● Clear or normal
● Rales (height of rales when patient sitting upright should be noted)
● Decreased breath sounds or dullness
● Rhonchi
● Wheezing
Other findings (e.g., pleural rub) may also be noted.
d
c
e
c
s
h
i
t
I
r
t. Laboratory Data
any routine and specialized laboratory tests may be
elevant to management and tracking of patients with
ardiac arrhythmias. Ejection fraction may influence the
emodynamic consequences of arrhythmias, both supraven-
ricular and ventricular, and has a significance influence on
rognosis. Ejection fraction may relate to risk of toxicity
ssociated with pharmacologic antiarrhythmic therapy.
hus, accurate quantification of ejection fraction, as well as
he presence of other manifestations of ventricular dysfunc-ocument in patients with arrhythmias. Evaluation of myo-
ardial ischemia and coronary anatomy is usually not nec-
ssary in patients with supraventricular arrhythmias and
onduction abnormalities, unless indicated by clinical pre-
entation. However, with the exception of patients who
ave one of the well-recognized syndromes associated with
diopathic ventricular tachycardia, most patients with ven-
ricular arrhythmias should have evaluation for ischemia.
schemia may directly cause certain ventricular tachyar-
hythmias. Furthermore, correction of ischemia may lessen
he frequency and severity of ventricular arrhythmias andion, such as ventricular aneurysms, may be important to improve the overall prognosis.
DATA ELEMENT DEFINITION
jection fraction (EF) Number measured or estimated. Indicate date of EF measurement.
● Quantitative measurement of EF is preferred over qualitative measurement.
● Quantitative:
— EF, measured in percent.
— When a quantitative range is given, the midpoint of the range.
● Qualitative:
— Normal (corresponds to left ventricular EF [LVEF] 50%).
— Mildly diminished (corresponds to LVEF 41% to 49%).
— Moderately diminished (corresponds to LVEF 26% to 40%).
— Severely diminished (corresponds to LVEF 25% or less).
When multiple determinations are present, the hierarchy should be:
● MRI
● Radionuclide ventriculography
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jection fraction (EF)
(continued)
● Contrast ventriculography
● Echocardiography
● Gated myocardial perfusion imaging
● Other
Specify imaging technique and date of most recent measurement.
all motion abnormalities Specify whether:
● General or
● Regional (akinesis, hypokinesis, dyskinesis, aneurysm)
Identify segment
Specify imaging technique and date of most recent exam.
ight ventricular size
and function
Description of right ventricular size and function. Specify whether normal or abnormal.
Specify technique and date of most recent exam.
omplete blood count (CBC) Indicate value and date performed.
emoglobin Serum hemoglobin (mg/dl)/hematocrit.
Normal range: M: 14 to 18 g/dl; F: 12 to 16 g/dl
latelet count Indicate value and date performed.
Normal range: 1.3 to 4.0  105/mm3
ed blood count Indicate value and date performed.
Normal range: 4.15 to 4.90  106/mm3
hite blood count Indicate value and date performed.
Normal range: 4.3 to 10.8  103/mm3
lood urea nitrogen (BUN) Indicate value and date performed.
Normal range: 10 to 20 mg/dl
erum creatinine Serum creatinine level (mg/dl or mmol/l).
Normal range: 1.5 mg/dl
erum albumin Indicate value and date performed.
Normal range: 3.5 to 5.5 g/dl
otassium Serum potassium (mg/dl or mmol/l)
Normal range: 3.5 to 5.0 mmol/l
odium Indicate value and date performed.
Normal range: 136 to 145 mmol/l
alcium Indicate value and date performed.
Normal range: 9 to 10.5 mg/dl
agnesium Indicate value and date performed.
Normal range: 1.5 to 2.0 mEq/l
lucose (fasting) Indicate value and date performed.
Normal range: 3.9 to 5.5 mmol/l
emoglobin A-1-C Indicate value and date performed.
Normal range: 3.8% to 6.4%
otal cholesterol Indicate value and date performed.
DL cholesterol Indicate value and date performed.
DL cholesterol Indicate value and date performed.
riglycerides Indicate value and date performed.
hyroid stimulating hormone
(TSH)
Indicate value and date performed.
Normal range: 0.4 to 5.0 mU/l
nternational Normalized Ratio
(INR)
Measure INR for assessment of anticoagulation status/prothrombin time.
oal INR Indicate the listed Goal INR for the patient
— 2.5 to 3.5
— 2.0 to 3.0
— Other (specify goal INR range and reason)
rain-natriuretic peptide (BNP)
or N-terminal BNP
Indicate value and date performed.
nflammatory markers Indicate value and date performed.
Examples of inflammatory markers may be C-reactive protein, interleukin 6 (IL-6), tumor necrosis factor,
sedimentation rate, and so on.
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oronary angiography performed Coronary angiography with or without left heart catheterization. Documented findings may include:
● Stenosis of any epicardial coronary artery (right, left anterior descending, circumflex) or major branch
(diagonal, marginal).
● Degree (percentage) of stenosis should be specified. Coronary arteries may have insignificant or no stenosis.
● Greatest stenosis assessed in bypass graft.
● Congenital anomaly of coronary arteries; specify whether present or absent.
Indicate date of most recent exam.
eft heart catheterization Left heart catheterization, with or without coronary angiography or ventriculography. Documented findings may
include:
● Left ventricular end-diastolic pressure (mm Hg). Pressure from left ventricular catheter at end-diastole.
● Left ventriculography EF. Percentage 5% to 90% from left ventricular injection.
Indicate date of most recent exam.
ight heart catheterization Right heart catheterization, with or without angiography. Documented findings may include:
● Right atrial pressure (mm Hg): mean right atrial pressure.
● Pulmonary artery systolic pressure (mm Hg): systolic pulmonary pressure from pulmonary artery catheter.
● Pulmonary artery diastolic pressure (mm Hg): diastolic pulmonary pressure from pulmonary artery catheter.
Mean pulmonary artery occlusion pressure from pulmonary artery catheter (wedge pressure, mm Hg).
Indicate date of most recent exam.
ongenital heart disease Diagnosis of congenital anomaly confirmed by angiography, saturation runs, and/or pressure measurements.
diagnosis. Noninvasive Diagnostic Procedures
DATA ELEMENT DEFINITION
. Echocardiography
CG Indicate type of echocardiogram performed (check all that apply):
● Transthoracic echocardiogram (TTE)
● Transesophageal echocardiogram (TEE)
● Intra-cardiac echocardiography
Indicate date of most recent exam.
ssessment of inter- and intra-
ventricular dyssynchrony on
echocardiography
Echocardiographic modality to assess left ventricular dyssynchrony. Specify what method used to judge
dyssynchrony:
● Tissue Doppler imaging
● Strain rate
● Other (specify)
eft atrial (LA) size—M-mode
on echocardiography
LA size, using the “leading edge to leading edge” method, in centimeters, measured from M-mode in the
parasternal long-axis view at the end of ventricular systole. It is often classified as follows:
● Normal size: 4.0 cm.
● Mild enlargement: 4.1 to 4.5 cm.
● Moderate enlargement: 4.6 to 5.5 cm.
● Severe enlargement: 5.5 cm.
A volume on echocardiography On 2-dimensional imaging (2D), using the LA areas traced in the 4- and 2-chamber views as calculated
by the standardized methods (e.g., Simpson’s method of disks).
eft ventricular diastolic diameter
on echocardiography
Left ventricular diameter measured at end ventricular diastole (in centimeters). Indicate whether by
M-mode or 2D.
eft ventricular systolic diameter
on echocardiography
Left ventricular diameter measured at the end of ventricular systole, in centimeters.
Indicate whether by M-mode or 2D.
eft ventricular diastolic function
on echocardiography
Assessment in normal sinus rhythm from a 2D apical view (either 2- or 4-chamber) of left ventricular inflow
pattern, pulmonary venous inflow pattern, or tissue Doppler imaging. Categories include:
● Normal
● Impaired relaxation (Grade I)
● Pseudonormal (Grade II)
● Restrictive, reversible (Grade III)
● Restrictive, irreversible (Grade IV)
● Not obtained
eft ventricular wall thickness on
echocardiography
Left ventricular end-diastolic thickness of septal and posterior walls as measured in the parasternal long-
axis view (in centimeters). Indicate whether by M-mode or 2D.
hrombus with location on
echocardiography
Clot within the cavities of the cardiac structures. Presence is considered to be definite if 3 of the following 5 criteria
are present:
● Clear borders
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hrombus with location on
echocardiography (continued)
● Echogenicity from the surrounding structures
● Independent mobility
● Longest diameter 15 mm
● Seen in more than one echocardiographic plane
Indicate location (check all that apply):
● LA appendage
● Left atrium
● Right atrium
● Right atrial appendage
● Left ventricle
● Right ventricle
pontaneous echo contrast
with location
Dynamic, swirling smoke-like echoes, usually within the left atrium or the LA appendage, but also occasionally
seen in other chambers. These echoes represent a marker of stasis and are distinct from “white noise artifact.”
Indicate location, noting all that apply:
● LA appendage
● Left atrium
● Right atrium
● Left ventricle
● Right ventricle
Grade as “present” or “absent.”
. Electrocardiography
eart rate on electrocardiogram Heart rate in beats per minute (bpm) as measured on electrocardiogram.
CG pattern of previous
myocardial infarction
● Indicate if pathologic Q waves are present, characterized as Q waves more than 40 ms in duration and/
or greater than or equal to one-quarter the R-wave amplitude.
● Indicate if there is a loss of R waves consistent with prior infarction
● Indicate region of infarction by ECG (check all that apply):
— Inferior
— Posterior
— Septal
— Anterior
— Lateral
CG pattern of left ventricular
hypertrophy (LVH)
Specify criteria. The following criteria have been validated prospectively in clinical studies:
● Sokolow-Lyon Voltage: SV1  RV5 or RV6 35 mm (does not require gender or age adjustment), or R
wave in aVL 11 mm.
● Cornell Voltage: RaVL  SV3 20 mm in women or 28 mm in males.
● Cornell Product: Cornell voltage times the QRS duration 2,440 ms (in women, 6 mm is added to
their Cornell voltage).
● Romhilt-Estes Score: LVH is likely with 4 or more points. LVH is present with 5 or more points:
— Amplitude of R or S wave in limb leads 2.0 mV, or S wave in
V1 or V2 3.0 mV, or R wave in V5 or V6 3.0 mV  3 points.
— ST-segment changes with or without digitalis  1 or 2 points, respectively.
— LA abnormality  3 points.
— Left-axis deviation 30° or more  2 points.
— QRS duration 90 ms  1 point.
— Intrinsicoid deflection in V5 or V6  0.05 to 0.07 s.
CG pattern of right ventricular
hypertrophy (RVH)
ECG manifestations of RVH are variable, and must include a QRS duration of 0.12 s and at least one
or more of the following. The criteria may be altered in the presence of severe chronic lung disease.
● Right-axis deviation (110°)
● Dominant R wave:
— R/S ratio in V1 or V3R 1, or R/S ratio in V5 or V6 1
— R wave in V1 7 mm
— R wave in V1  S wave in V5 or V6 10.5 mm
— rSR= in V1 with R= 10 mm
— qR complex in V1
● Secondary ST-T changes in right precordial leads
● Right atrial abnormality
● Onset of intrinsicoid deflection in V1 between 0.035 and 0.055 s
CG pattern of complete bundle
branch block
Specify if any of the following are present:
● RBBB
● LBBB
● Nonspecific IVCD
CG pattern of WPW Indicate if characteristic delta wave is present.
CG pattern of atrial abnormality Indicate if left, right, or biatrial abnormality is present.Continued on next page
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T interval on ECG ● Measurement of the average QT interval and heart rate over at least 3 complexes of ECG recording of
multiple (at least 3) ECG leads.
● QT is measured from the earliest onset of the QRS in multiple leads to the latest termination of the T
wave in these leads. (The U wave should be excluded from the measurement. For patients with large U
waves that interrupt the termination of the T wave, the T wave should be extrapolated as the tangent to
the maximum downstroke to the isoelectric baseline.) Alternatively, if only a single ECG lead is
recorded at a time, the QT interval is the longest QT measured in any lead.
● The correction of the QT interval for heart rate (QTc) can be performed by many techniques, but the
simplest and most widely used is the Bazett formula:
QTc  measured QT⁄square root of the preceding RR interval in seconds.
T dispersion Difference between the longest and shortest individually measured QTc interval in each of the 12 leads of
the standard ECG (or, in some cases, in precordial mapping).
. Exercise Testing
ormal exercise test ● Normal exercise tolerance
● No evidence of exercise-induced ischemia
● No arrhythmia induced
xercise test Indicate the following:
● Type of exercise or stress
● Type of imaging agent
xercise protocol State protocol employed (e.g., Bruce, etc.). Specify if treadmill, supine bicycle, and so on.
xercise test imaging modalities Indicate imaging modality used (check all that apply):
● Perfusion imaging
— Thallium
— Other
● RNA imaging: state rest and exercise EF
● Echocardiographic imaging: state rest and exercise EF and whether regional wall motion abnormalities
appeared during exercise.
ength of exercise State duration in minutes and seconds.
istance walked—6-min walk Distanced walked during 6-min walk, in feet or meters.
aximum heart rate and blood
pressure
State maximum heart rate and blood pressure achieved in beats per minute.
Indicate what percent of age-related target heart rate achieved.
aximal (symptom limited) or
submaximal test
Indicate whether exercise test was maximal or submaximal.
etabolic equivalents (METS)
achieved
Indicate the level and number of METS achieved.
vidence of ischemia on exercise
test
Indicate evidence of ischemia (check all that apply):
● ECG: ST-T wave abnormalities (specify type)
● Angina provoked during exercise
● Hypotensive response during exercise. State whether blood pressure fell at peak exercise
● Ischemia-mediated arrhythmias occurred (e.g., polymorphic VT/VF)
rrhythmia occurred on exercise
test
Specify type of arrhythmia and indicate whether it occurred during or after exercise.
. Other Noninvasive Diagnostic Procedures
RI MRI (may include angiography) of the chest. Steady-state, free-procession cine MRI for calculation of
EF. MRI may also be used to define cardiac anatomy, as well as evaluate myocardial perfusion and
viability.
adionuclide ventriculography
(RVG)
Cardiac blood pool imaging (first pass or gated equilibrium) with or without stress.
Documented findings may include:
LVEF: 5% to 90% for left ventricle.
Right ventricular EF: 5% to 90% for right ventricle.
yocardial perfusion imaging Radionuclide myocardial perfusion imaging (planar or single-photon emission computed tomography)
with or without stress. Documented findings may include:
● Stress-induced perfusion abnormalities.
● Fixed perfusion abnormalities.
● Perfusion imaging LVEF: 5% to 90% for left ventricular from perfusion (technetium) imaging.
omputed axial tomography
(CT scan)
CT scan can be either cine CT for left ventricular function, electron beam CT for coronary calcium
content, or high-resolution CT for vascular anatomy (coronary anatomy, PVs). Specify.
icrovolt T-wave alternans
(MTWA)
Report the following findings:
● Treadmill test or atrial pacing
● Results
— Positive: MTWA present at heart rate 110 bpm (cycle length: 545 ms)
— Negative: MTWA not present at heart rate 110 bpm (cycle length: 545 ms)
— Indeterminate: unable to achieve target heart rate or stable tracing
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ontinuous ambulatory
ECG monitor
Report the following findings:
● Specify type of ambulatory ECG monitor used (e.g., looping event monitor, implantable looping event
monitor, Holter monitor, etc.)
● Duration of monitoring (usually 24 to 48 h for Holter monitor)
● Quality of tracings
● Utilization of patient diary
● Correlation between symptoms and rhythm
● Frequency of ventricular ectopy: per hour or per 24 h
● Specify whether uniform or multiform ectopy
● Mean 24-h heart rate, as well as minimum and maximum for patients in AF
● Number of pauses 2.4 s
● Specify arrhythmias documented
eart rate variability Two types of recordings should be used whenever possible:
1. Short-term recordings of 5 min made under physiologically stable conditions processed by
frequency domain methods and/or
2. Nominal 24-h recordings processed by time-domain methods
(See Appendix B for frequency and time domain units.)
ignal-averaged ECG (SAECG) Report the following findings:
● Specify high pass filter setting (25 or 40 Hz)
● Filtered QRS duration (in milliseconds)
● Duration of terminal filtered QRS with amplitude 40 mV (in milliseconds)
● Root mean square amplitude of terminal 40 ms (in mV)
● Mean noise level (in mV)
aroreflex sensitivity (BRS) Report BRS value (in milliseconds per mm Hg).
eart rate turbulence (HRT) A measure of the autonomic response to alteration in blood pressure following a PVC. HRT correlates
with BRS and may be measured from ambulatory ECG recordings. HRT is characterized by two
parameters: turbulence onset (TO) and turbulence slope (TS).
ilt table tests Report the following findings:
● Degree of head-up tilt (60°, 70°, 75°, 80°)
● Duration of head-up tilt
● Provocative pharmacological testing (adenosine/nitroglycerine/other, specify)
● Test results (positive/negative/equivocal):
— A positive test for neurocardiogenic syncope characterized by either: 1) a drop in systolic blood
pressure 80 mm Hg with a slowing or no changes in heart rate accompanied by typical
symptoms (vasodepressor response), or 2) a slowing in sinus rate or sinus arrest (asystole,
cardioinhibitory response).
— A positive test for POTS is characterized by an orthostatic rise in heart rate of 30 bpm above
baseline or 120 bpm within the first 10 min of head-up tilt without significant fall in
systolic blood pressure (10 mm Hg), accompanied by typical symptoms.
— A negative test is defined as completion of the testing protocol without significant hypotension or
typical symptoms.
— An equivocal test is defined as failure to induce syncope or meet the aforementioned criteria.
● Response to carotid sinus massage.. Electrophysiology Study
ot all elements of the electrophysiologic evaluation may be necessary or appropriate for every patient.
DATA ELEMENT DEFINITION
. Indications for Diagnostics
valuation of specific arrhythmia Indicate the type of arrhythmia prompting the electrophysiology (EP) study:
● Bradyarrhythmia
● Tachyarrhythmia
valuation of prior antiarrhythmic
treatment
Indicate prior antiarrhythmic treatment:
● Antiarrhythmic drug
● Catheter ablation
● Arrhythmia surgery
● Pacemaker function
● Cardioverter/defibrillator function
● Other (specify)
Continued on next page
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valuation of event/symptoms
suggesting arrhythmia
Indicate the event/symptom which prompted the EP study:
● Cardiac arrest
● Syncope
● Palpitations
valuation of risk for ventricular
tachyarrhythmia
Programmed stimulation to evaluate the presence of inducible VT or VF.
. Description of Procedure
atheters used Indicate type of catheters used in procedure.
atheter insertion Indicate where catheters were inserted:
● Vein (specify)
● Artery (specify)
● Transcutaneous
atheter placement Indicate cardiac chamber where catheters were placed:
● Right atrium
● Right ventricle
● Left atrium
● Left ventricle
● Coronary sinus (CS)
● Other cardiac veins
● His bundle position
● Pericardium
● PV
● Vena cava
● Pulmonary artery
● Other (specify)
ntiarrhythmic medications
present at time of procedure
Indicate if the following medications are present at time of procedure:
● Digitalis
● Beta-adrenergic blocking agents
● Calcium channel blocking agents
● Primary antiarrhythmic medications
If the patient is not receiving any drug at the actual time of procedure, indicate time duration discontinued prior to
procedure.
rugs administered for sedation/
general anesthesia
Specify drugs administered for sedation or for general anesthesia.
rugs administered for therapy/
diagnostics
Indicate therapeutic and/or diagnostic drugs administered, such as isoproterenol, epinephrine, dopamine,
aminophylline, atropine, adenosine, beta-blockers, ibutilide, verapamil, procainamide, and so on.
. Diagnostic Evaluation (see Appendix A for a supplemental dictionary of arrhythmia terms used throughout this section)
. Sinus Node Function
inus node function ● Sinus node recovery time
— Maximal time, in milliseconds, from last paced atrial depolarization to first sinus
return cycle, at any pace cycle length. Stimulation and measurement are
performed as close to sinus node as possible.
● Corrected sinus node recovery time (sinus node recovery time minus sinus cycle length)
● Other
rrhythmias observed—sinus
node function
● Physiological ST
● Inappropriate ST
● Sinus node re-entry tachycardia
● Sinus node exit block
● Sinus arrest
● Other (specify)
. Atrial Function
ntra-atrial conduction Indicate sites measured. Local activation time is measured form a reference point, such as P-wave onset, to the
first intrinsicoid deflection on the local electrogram.
efractory period—Atrial function ● Effective refractory period: the longest S1S2 interval during atrial pacing, or A1S2 interval during sinus rhythm,
at which S2 does not depolarize the atrium.
● Functional refractory period: the shortest obtainable A1A2 interval at any specified recording site.
● Relative refractory period: the longest S1S2 interval at which A1A2 exceeds S1S2.
trial stimulation performed ● Straight pacing cycle lengths (enter values)
● Atrial extrastimuli (specify number delivered) and drive cycle lengths
● Sites stimulated (e.g., high right atrium, CS, other)
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rrhythmias observed—Atrial
function
Specify arrhythmia observed:
● AF (specify):
— Focal
— Re-entrant
— Both focal and re-entrant
— Other (specify)
— Unknown: current understanding of the mechanism of AF is incomplete. Multiple
mechanisms may be responsible for AF in any individual patient. Different
mechanisms may be responsible for initiation versus maintenance of the arrhythmias.
● Focal AT (specify mechanism)
● Multi-focal AT
● Macro–re-entrant AT
— CTI dependent
— Non-CTI dependent
● Other (specify)
Specify cycle length and morphology
ow was arrhythmia induced—
Atrial function
Specify how arrhythmia was induced.
● Straight pacing
● For programmed stimulation, state drive cycle length(s) and number of extrastimuli
● Stimulation site
● Whether isoproterenol or other pharmacologic agents were required for induction
● Arrhythmia occurred spontaneously
● Not inducible
uration of arrhythmia—Atrial
function
State duration, as appropriate, in number of complexes, or seconds to minutes, or sustained (30 s or requiring
termination in 30 s because of hemodynamic compromise).
ow did the arrhythmia
terminate—Atrial function
Specify how arrhythmia was terminated:
● Self-terminated
● Pacing
● Extrastimuli
● Drug (specify)
● Cardioversion
● Ablation
. AV Node Function
trio-His (AH) interval This measurement is obtained using the AH interval identified on the His bundle electrogram. The AH interval is
measured from the first rapid deflection of the atrial electrogram to the earliest onset of His bundle activation.
nterograde refractory period—
AV node function
● Effective: the longest A1A2 interval measured on the His bundle electrogram at which A2 does not conduct to
the His bundle. Programmed atrial stimulation is done during sinus rhythm or atrial pacing at a fixed cycle
length for 8 beats.
● Functional: the shortest obtainable H1H2 interval during programmed atrial stimulation.
● Relative: the longest A1A2 interval at which H1H2 is greater than A1A2.
etrograde refractory period
of the ventriculoatrial
conduction system
● Effective: the longest V1V2 interval introduced during programmed ventricular stimulation at which V2 does
not conduct to the atrium.
● Functional: the shortest obtainable A1A2 interval during programmed ventricular stimulation.
enckebach cycle length ● Anterograde cycle length: during atrial pacing with progressive shortening of the drive cycle length by 10 to 20
ms, the longest pacing cycle length with Wenckebach AV node conduction.
● Retrograde cycle length: during ventricular pacing with progressive shortening of the drive cycle length by 10
to 20 ms, the longest pacing cycle length with Wenckebach ventriculo-atrial conduction.
● When determining the Wenckebach cycle length, the stimulation site should be specified.
rrhythmias observed—
AV node function
Specify arrhythmia observed:
● AV node re-entry
— Slow-fast (typical)
— Fast-slow (atypical)
— Slow-slow
● Non–re-entrant tachycardia related to dual pathways
● Focal junctional tachycardia
● Nonparoxysmal junctional tachycardia
ow was arrhythmia induced—
AV node function
Specify how arrhythmia was induced.
● Straight pacing
● For programmed stimulation, state drive cycle length(s) and number of extrastimuli
● Stimulation site
● Whether isoproterenol or other pharmacologic agents were required for induction
uration of arrhythmia—
AV node function
State duration, as appropriate, in number of complexes, or seconds to minutes, or sustained (30 s or requiring
termination in 30 s because of hemodynamic compromise).Continued on next page
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ow did the arrhythmia
terminate—AV node function
Specify how arrhythmia was terminated:
● Self-terminated
● Pacing
● Extrastimuli
● Drug (specify)
● Cardioversion
● Ablation
. His-Purkinje System Function
is-ventricular (HV) interval The HV interval is measured from the earliest onset of activation of the His bundle to the earliest onset of
ventricular activation using any intracardiac recording or surface ECG lead.
efractory period—His-Purkinje
system
Specify type of refractory period:
● Anterograde effective: the longest H1H2 interval during programmed atrial stimulation at which H2 does not
conduct to the ventricle.
● Functional: the shortest obtainable V1V2 interval during programmed atrial stimulation.
● Relative: the longest H1H2 interval at which V1V2 exceeds H1H2.
ntra or infra-Hisian block Block within or below the His bundle recording may occur during sinus rhythm, atrial pacing, or programmed
atrial stimulation. Block during atrial pacing may be physiologic or pathologic. Block that occurs with the
sudden onset of rapid pacing is typically physiologic. Infra-Hisian block that occurs during atrial pacing with
progressive shortening of the pacing cycle length is typically pathologic. Under certain circumstances when
paroxysmal intra- or infra-Hisian block is strongly suspected but baseline evaluation is not markedly
abnormal, function of the His-Purkinje system may be evaluated (incremental pacing and programmed
stimulation) under pharmacologic stress using agents such as procainamide.
. Accessory Pathway (Bypass Tract) Function
ccessory pathway (bypass tract) Specify number and location of accessory pathway(s). For each accessory pathway, indicate:
● Proximal insertion site
● Distal insertion site
● Anterograde conduction is present (yes/no)
● Retrograde conduction is present (yes/no)
● Accessory pathway(s) having decremental conduction properties (specify anterograde, retrograde, which bypass tract?)
lock cycle length—
Accessory pathway
Indicate the block cycle length of the accessory pathway:
● Anterograde: during incremental atrial pacing, the longest A1A1 interval without 1:1 conduction over the
accessory pathway.
● Retrograde: during incremental ventricular pacing, the longest V1V1 interval without 1:1 conduction over the
accessory pathway.
ffective refractory period of
accessory pathway
Indicate the effective refractory period of the accessory pathway:
● Anterograde: the longest A1A2 interval, measured at an atrial site closest to the atrial insertion of the accessory
pathway at which A2 does not conduct over the accessory pathway.
● Retrograde: the longest V1V2 interval at which V2 does not conduct over the accessory pathway.
● Functional: during programmed ventricular stimulation, the shortest obtainable A1A2 interval resulting from
conduction over a bypass tract.
hortest pre-excited RR interval
during AF
During spontaneous or provoked AF, specify the shortest observed consecutive pre-excited RR interval.
rrhythmias observed—
Accessory pathway
Specify arrhythmia observed:
● Orthodromic SVT
● Antidromic SVT
● Other: passive bystander pathway
For each observed tachycardia, specify:
● Cycle length
● QRS morphology
● Tachycardia duration (nonsustained vs. sustained)
● Anterograde pathway
● Retrograde pathway
ow was arrhythmia induced—
Accessory pathway
Specify how arrhythmia was induced.
● Straight pacing
● For programmed stimulation, state drive cycle length(s) and number of extrastimuli
● Stimulation site
● Whether isoproterenol or other pharmacologic agents were required for induction
uration of arrhythmia—
Accessory pathway
State duration, as appropriate, in number of complexes, or seconds to minutes, or sustained (30 s or requiring
termination in 30 s because of hemodynamic compromise).
ow did the arrhythmia
terminate—Accessory pathway
Specify how arrhythmia was terminated.
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. Ventricular Function
ntraventricular conduction Specify sites measured. Local activation time is measured from a reference point, such as QRS complex onset, to
the first intrinsicoid deflection on the local electrogram during sinus rhythm or tachycardia.
efractory period—Ventricle ● Effective: the longest S1S2 interval during ventricular pacing, or V1S2 interval during sinus rhythm at which S2
does not depolarize the ventricle.
● Functional: the shortest obtainable V1V2 interval at any specified recording site.
● Relative: the longest S1S2 interval at which V1V2 is greater than S1S2.
entricular stimulation performed ● Straight pacing cycle length ___ (enter values)
● Ventricular extrastimuli (specify number delivered) and drive cycle lengths
● Long-short stimulation
● Sites stimulated (right ventricular apex, right ventricular outflow tract, right ventricle septum, left ventricle)
rrhythmias observed—Ventricle ● Specify arrhythmia observed:
● Non-sustained VT uniform
● Non-sustained VT polymorphic
● Sustained VT uniform
● Sustained VT polymorphic
● VF
● Ventricular flutter
● Other (specify)
Specify cycle length and morphology.
ow was arrhythmia induced—
Ventricle
Specify how arrhythmia was induced.
● Straight pacing
● For programmed stimulation, state drive cycle length(s) and number of extrastimuli
● Stimulation site
● Whether isoproterenol or other pharmacologic agents were required for induction
uration of arrhythmia—
Ventricle
State duration, as appropriate, in number of complexes, or seconds to minutes, or sustained (30 s or requiring
termination in 30 s because of severe hemodynamic compromise).
ow did the arrhythmia
terminate—Ventricle
Specify how arrhythmia was terminated.
● Self-terminated
● Pacing
● Extrastimuli
● Drug (specify)
● Cardioversion
● Ablation
. Therapeutic Procedures
. Indication for Therapeutic Procedures
ndications for catheter ablation The reason for undergoing attempted ablative therapy (may be more than one):
● Symptoms
● Desire for drug-free lifestyle
● Stroke prophylaxis
● Sudden death prophylaxis
● Frequent ICD discharges
atheter ablation performed Indicate whether ablation was performed.
argeted substrate for ablation 1. Inappropriate ST
● Sinus node
2. AF
● PV focus
● Segmental PV isolation
● Ostial PV isolation
● Extra-ostial PV isolation
● Linear ablation
● Substrate modification
● AV junctional ablation
● AV junctional modification
3. Atrial tachycardia
● Right atrial focal
● LA focal
● Linear ablation of CTI
● Substrate modification (includes linear ablations between scars and anatomical boundaries)
4. Accessory pathway
● Right free wall
● Left free wall
● AnteroseptalContinued on next page
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argeted substrate for ablation
(continued)
● Mid septal
● Right posteroseptal
● Left posteroseptal
● Epicardial, including:
— Within coronary venous system, including CS diverticulum
— Appendage to ventricular connections
● Decremental atriofascicular or antrioventricular
● Nodofascicular and nodoventricular
● Fasciculoventricular
5. AV nodal re-entry
● Slow AV nodal pathway
● Fast AV nodal pathway
6. Right VT (may choose more than one)
● Focal outflow
● Focal other
● Re-entrant slow conduction zone
● Substrate modification
7. Left VT (may choose more than one)
● Focal outflow
● Focal other
● Left fascicle
● Re-entrant slow conduction zone
● Substrate modification
blation procedure 1. Targeting method (may choose more than one)
● Activation mapping
● Pace mapping
● Entrainment mapping
● Anatomic fluoroscopy-based
● Three-dimensional (3D) electroanatomical mapping
● 3D non-contact mapping
● Intracardiac echo-guided anatomical ablation
● Other, specify
2. Energy source
● Radiofrequency, standard (4- or 5-mm tip)
● Radiofrequency, large tip (8- or 10-mm tip)
● Radiofrequency, cooled, closed loop
● Radiofrequency, cooled, open perfused
● Cryothermic
● Ultrasound
● Laser
● Microwave
● Other, specify
3. Number of ablative lesions
4. Procedure times
● Total procedure time (minutes): time from first needle insertion to place catheters to time of last catheter
removal (excluding removal of temporary pacing catheters for heart block)
● Observation time (minutes) post-ablation
● Total fluoroscopy time (total time on pedal, minutes)
. Outcome of Ablation
nappropriate ST Indicate inappropriate ST:
● Normalization of sinus node function (see Appendix A)
● Sinus bradycardia (inappropriate for conditions) or arrest
● Persistent inappropriate sinus tachycardia
● Persistent symptoms despite good electrophysiologic outcome
F Indicate AF:
● Acute outcome:
— Termination of fibrillation during ablation (location)
— Non-inducibility of fibrillation
— Electrical PV isolation (specify which vein[s])
— Voltage reduction inside isolated regions to 0.1 mV
● Long-term outcome:
— Method of assessment (symptoms, event monitor, 24-h monitor, pacemaker log)
— Absence of symptoms (palpitations, lightheadedness, dyspnea, etc.)
— Absence of ECG evidence of fibrillation
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T Indicate AT:
● Absence of spontaneous/inducible tachycardia
● Persistence of spontaneous/inducible tachycardia
ccessory pathway Indicate accessory pathway:
● Anterograde conduction (delta wave, intracardiac preexcitation):
— Elimination of anterograde conduction
— Persistence of anterograde conduction
● Retrograde conduction:
— Elimination of retrograde conduction
— Persistence of retrograde conduction
 Without SVT
 With SVT
V junction Indicate AV junction:
● Slow pathway ablation:
— Elimination of slow pathway conduction
— Persistence of slow pathway conduction
 Without echoes
 With echoes (specify number) but no SVT
 Persistence of spontaneous or inducible SVT
● Fast pathway ablation:
— Elimination of fast pathway conduction
— Persistence of fast pathway conduction
 AV nodal ablation
— Elimination of conduction
 With escape rhythm 40 bpm
 Without escape rhythm 40 bpm
● His bundle ablation:
— Elimination of ectopic focus/tachycardia
— Persistence of ectopic focus/tachycardia
— Elimination of conduction
ight VT Indicate right ventricular tachycardia:
● Absence of spontaneous/inducible VT
● Persistence of spontaneous/inducible VT (specify which)
— Sustained or non-sustained
eft VT Indicate left VT:
● Absence of spontaneous/inducible VT of any kind
● Persistence of spontaneous/inducible VT (specify which)
— Sustained or non-sustained
— Mappable or non-mappable
. Other EP Procedures
. Pacemaker/ICD Implantation
acemaker implantation 1. Specify indication (all that apply):
● Sinus node dysfunction
● AV block
● AF
● Neurocardiogenic syncope (carotid sinus hypersensitivity and vasovagal syncope)
● Hypertrophic cardiomyopathy
● Medically refractory congestive HF
● Supraventricular tachyarrhythmias (historically)
2. Specify type of pacemaker implanted:
● Single chamber (atrial)
● Single chamber (ventricular)
● Dual chamber (both atrial and ventricular)
● Biventricular of any type
3. Venous access:
● Subclavian
● Axillary
● Internal jugular
● External jugular
● Cephalic
● Femoral
● Other
Continued on next page
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acemaker implantation
(continued)
4. Endocardial Lead Positions:
● Atrial:
— Right atrial appendage
— Right atrial free wall
— Right atrial septum
— Adjacent to coronary sinus ostium
— Other
● Ventricular:
— Right ventricular apex
— Right ventricular inflow
— Right ventricular outflow
— Other
5. Epicardial lead positions:
● Right atrial
● LA
● Right ventricle
● Left ventricle
6. Coronary sinus:
● Tributaries that allow atrial stimulation
● Tributaries that allow ventricular stimulation
— Unsuccessful catheterization of coronary sinus or target branch
— Stable electrode position in vein branch
— Consistent left ventricular capture without diaphragmatic stimulation
7. Specify if capable of:
● Burst pacing
● Anti-tachycardia pacing
Specify date of current implant. Specify manufacturer and model number.
efibrillator implantation Specify indication:
● AF
● Secondary prevention of cardiac arrest
● Primary prevention of cardiac arrest. High risk for VT (e.g., ischemic heart disease, hypertrophic
cardiomyopathy, Brugada syndrome, long QT syndrome, HF)
● Syncope with inducible VT
Specify type of defibrillator implanted:
● Single chamber
● Dual chamber
● Biventricular
Subcutaneous array
Specify if capability exists:
● Burst pacing
● Anti-tachycardia pacing
● Cardioversion
. Lead Extraction
ndications Specify indications for lead extraction:
● Infection
● Lead malfunction
● Venous obstruction
● Other (specify)
ake and model number of
extracted device/lead(s)
● Specify extracted device make and model number
● Specify extracted lead(s) make and model number
ocation of device/lead(s)
extracted
● Specify location (insertion site/chamber of heart) of device generator
● Specify location (insertion site/chamber of heart) of lead(s) extracted
ethod of extraction Indicate combination of methods of extraction:
● Laser sheaths
● Electrosurgical dissection sheaths (EDS)
● Mechanical sheaths (steel, polypropylene, or polytetraflouroethylene)
● Femoral extraction tools and/or snares
● Locking stylets
● Other (specify)
. Cardioversion
ndications Specify indication(s) for cardioversion and type of arrhythmia.
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ype of cardioversion Indicate the type of cardioversion used:
● External—Patch position:
— Anterior—Posterior
— Anterior—Lateral
— 4 patches (2 defibrillators in tandem)
— Other (specify)
● Internal—Lead position:
— Right atrium
— Other (specify)
● Specify waveform
— Monophasic, all types
— Rectilinear biphasic
— Truncated exponential biphasic
— Other, specify
● Pharmacologic:
— Procainamide (specify total dose and route)
— Ibutilide (specify total dose and route)
— Propafenone (specify total dose and route)
— Amiodarone (specify total dose and route)
— Verapamil (specify total dose and route)
— Diltiazem (specify total dose and route)
— Other (specify drug, total dose, and route)
● Hybrid (electric plus pharmacologic), as noted above.
umber of shocks delivered Indicate the number of shocks delivered during current session.
aximal energy used Indicate maximal energy used in current session.
ardioversion attempt 1. Medication: list generic name for medication used to attempt cardioversion for a patient from AF to normal
sinus rhythm. Indicate route of administration (intravenous or oral) and total daily dose and units.
(Include total dose until cardioversion or accepted failure.)
2. Internal cardioversion: for pharmacologic cardioversion, time frame for assessment will depend on medication
and route of administration (e.g., success for intravenous ibutilide may be within an hour from the end
of infusion, whereas success for oral amiodarone may be within several days).
3. External cardioversion: electric shock delivered to external parts.
4. Success of cardioversion: absence of AF or atrial flutter for at least 10 s following shock delivery or at any time
following antiarrhythmic administration.
omplications of cardioversion Include all complications occurring from the initiation of cardioversion attempt to 30 days after cardioversion.
Specify complication and categorize into:
● Anesthesia-related
● Thromboembolic
● Arrhythmic
● Pulmonary edema/HF
● Other
attern of recurrence After successful conversion.
● Immediate recurrence of AF (returns in 2 min)
● Subacute recurrence of AF (returns between 2 min and 14 days)
● Late recurrence of AF (returns after 14 days). Complications/Adverse Events
DATA ELEMENT DEFINITION
dverse events resulting from EP
study and/or ablation
Indicate adverse event(s) which occurred during or following EP study and/or ablation. Specify time of
occurrence relative to EP study/ablation:
● AV fistula
● Bleeding requiring transfusion
● Cardiac arrest
● Cardiac valve injury
— Specify affected valve
● Conduction block:
— Ongoing
— Resolved
● CVA/TIA
● Death
● Deep venous thrombosisContinued on next page
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dverse events resulting from EP
study and/or ablation
(continued)
● Drug reaction—anaphylaxis (specify drug implicated as cause of reaction)
● Endocarditis
● Esophageal fistula
● Hematoma
● Myocardial infarction
● Pericardial effusion without tamponade
● Pericardial tamponade
● Peripheral embolus
● Peripheral nerve injury
● Pneumothorax
● Phlebitis
● Phrenic nerve paralysis
● Pulmonary embolism
● PV stenosis
● Sepsis
● Other (specify)
● Major complication is one which requires intervention, prolongs hospital stay, or results in permanent
impairment.
dverse events resulting from
pacemaker/ICD implantation
Indicate adverse events occurring during or following pacemaker/ICD implantation. Specify time of
occurrence relative to pacemaker/ICD implantation:
● Arteriovenous fistula
● Cardiac arrest
● Cardiac valve injury
— Specify affected valve
● CVA/TIA
● Coronary venous dissection
● Death
● Drug reaction (predominantly antibiotic reaction if antibiotics administered during and/or after procedure)
● Hemothorax
● Infection related to device
● Intravenous contrast reaction (if contrast agents used for venous puncture)
● Lead dislodgement
● Lymphatic fistula/chylothorax
● Myocardial infarction
● Pocket hematoma
● Post-procedure bleeding
● Pneumothorax
● Pericardial tamponade
● Other (specify)
dverse events resulting from
lead extraction
Indicate adverse events occurring during or following lead extraction. Specify time of occurrence relative to
lead extraction:
● Bleeding
● Death
● Drug reaction (predominantly antibiotic reaction if antibiotics administered during and/or after procedure)
● Hemothorax
● Intravenous contrast agents
● Pneumothorax
● Pericardial tamponade
● Tricuspid valve damage
● VT
● VF
● Vascular tear/laceration or perforation
● Other (specify). Patient Management as a Result of Electrophysiology Studies
DATA ELEMENT DEFINITION
bservation and reassurance No specific antiarrhythmic therapy warranted.
harmacologic therapy
recommended
Indicate the pharmacologic therapy recommended as a result of the EP study:
● Antiarrhythmic drugs. Indicate specific drugs (i.e., digitalis, beta-blocker, calcium channel blocker, primary
antiarrhythmic agents).
● Nonantiarrhythmic drugs (i.e., aspirin, oral anticoagulation, etc.)
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harmacologic therapy
recommended (continued)
● Anti-ischemic therapy
● Other (specify)
valuation for myocardial
ischemia recommended
Indicate if EP study suggested need for evaluation for ischemia.
blation recommended Indicate if ablation was recommended as a result of EP study. Indicate patient response to ablation
recommendation:
● Yes, patient agreed to ablation
● No, patient declined to have ablation
urgery recommended Indicate if surgery was recommended as a result of EP study. Specify type:
● Myocardial revascularization
● Arrhythmia surgery
● Other (specify)
Indicate patient response to surgery recommendation:
● Yes, patient agreed to surgery
● No, patient declined to have surgery
acemaker implant recommended Indicate if a pacemaker implantation was recommended as a result of EP study (e.g., sinus node dysfunction,
AV conduction disturbance, syncope, prevention of AF, etc.).
Indicate patient response to pacemaker implant recommendation:
● Yes, patient agreed to pacemaker implantation
● No, patient declined to have pacemaker implanted
efibrillator implant recommended State indication for ICD (e.g., VT-sustained, cardiac arrest, primary prevention, AF, etc.)
Indicate patient response to defibrillator implant recommendation:
● Yes, patient agreed to defibrillator implantation
● No, patient declined to have defibrillator implanted
iventricular pacer recommended State indication for biventricular device (e.g., LBBB, IVCD, pace-dependent, etc.).
Indicate patient response to biventricular pacer implant recommendation:
● Yes, patient agreed to biventricular pacemaker implantation
● No, patient declined to have biventricular pacemaker implanted
iventricular ICD recommended State indication for biventricular device (e.g., LBBB, IVCD, pacer-dependent, etc.).
Indicate patient response to biventricular ICD implantation recommendation:
● Yes, patient agreed to biventricular ICD implantation
● No, patient declined to have biventricular ICD implanted
picardial pacer lead
recommended
State indication for epicardial pacer lead.
Indicate patient response to epicardial pacer lead recommendation:
● Yes, patient agreed to epicardial pacer lead
● No, patient declined to have epicardial pacer lead. Discharge Information
DATA ELEMENT DEFINITION
onantiarrhythmic cardiac
medication(s) prescribed
at discharge
Indicate specific nonantiarrhythmic cardiac medication(s) prescribed at discharge (i.e., aspirin, statins,
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers)
ntiarrhythmic drug(s) prescribed Indicate specific antiarrhythmic drug(s) prescribed at discharge (i.e., digitalis, beta-blocker, calcium channel
at discharge blocker, primary antiarrhythmic agents). Follow-Up
DATA ELEMENT DEFINITION
ecurrence of arrhythmia State arrhythmias that occurred during follow-up and time of occurrence in relation to EP study.
yncope after treatment Indicate if patient experienced syncope after treatment commenced.
esuscitated cardiac arrest—
Follow-up
Indicate if patient experienced sudden loss of consciousness requiring direct current cardioversion to restore
consciousness or stable blood pressure and rhythm.
pontaneous sustained VT—
Follow-up
Indicate if patient experienced spontaneous occurrence of VT 30 s in duration or requiring termination
due to hemodynamic compromise; assessed through electrocardiographic monitoring.
Continued on next page
SS
C
I
1
C
N
N
N
H
I
D
L
H
2390 Buxton et al. JACC Vol. 48, No. 11, 2006
ACC/AHA/HRS Clinical Data Standards December 5, 2006:2360–96DATA ELEMENT DEFINITION
pontaneous sustained VT
morphologies and rates—
Follow-up
Indicate spontaneous sustained VT morphology:
● Uniform:
— Describe bundle branch block type pattern
— Describe frontal plane QRS axis
— Describe rate or cycle length
● Polymorphic:
— Describe rate or cycle length
ymptoms occurring during
spontaneous sustained VT—
Follow-up
● Palpitation
● Dyspnea
● Diaphoresis
● Lightheadedness
● Chest discomfort
● Syncope
● None
ardioverter/defibrillator
discharges—Follow-up
Therapy delivered by an implanted caridoverter/defibrillator, either antitachycardia pacing or shock.
Indicate diagnosis from stored electrograms.
mplanted device lead
complications
Indicate complications occurring as a result of implanted device lead(s):
● Lead dislodgement
● Lead malfunction (specify type)
● Phrenic nerve stimulation
● Endocarditis or other infection
● Other (specify)
2-lead ECG—Follow-up State when and if 12-lead ECG performed and whether changed from baseline.
ardiac procedures since last
contact—Follow-up
Indicate cardiac procedures performed since last contact:
● CABG
● Angioplasty
● Other cardiac surgery (specify)
ew myocardial infarction—
Follow-up
Indicate if myocardial infarction has occurred since last contact.
ew onset angina or change in
pattern of previously stable
angina—Follow-up
Indicate date of symptom onset or documentation.
ew-onset HF—Follow-up Indicate date of symptom onset or documentation.
eart transplantation—Follow-up Indicate date of heart transplantation.
nterim hospitalization—Follow-up Indicate hospitalizations since last contact for:
● HF
● Myocardial infarction
● Ischemia
● Cardiac arrhythmia (new or recurrent—identify which)
eath Indicate classification of death:
● Sudden cardiac:
— Witnessed instantaneous in a previously stable patient. This may occur with or
without preceding signs or symptoms, or may occur immediately following
sudden dyspnea, lightheadedness, or palpitations.
— Unwitnessed. Patient found dead who at time of last witnessed contact was in
usual state of health without medical complaints or obvious difficulty. This
applies to patients dying during sleep.
Note: Whereas most sudden deaths seem to result from cardiac arrhythmias, sudden
death may also result from non-cardiac processes (e.g., acute pulmonary embolus,
rupture of abdominal aortic aneurysm). In most cases, documentation of the actual
cause of death is missing.
● Non-sudden cardiac. Includes deaths of patients in acute pulmonary edema; with severe, progressive
HF; cardiogenic shock; or after recent cardiac surgical procedure.
● Non-cardiac. Vascular death (thromboembolic event, acute hemorrhage, CVA, dissecting aneurysm), or
non-cardiovascular death (e.g., trauma, renal failure, cancer, sepsis, suicide).● Unknown. No information available regarding death event.. Medical Care Resource Utilization
DATA
ELEMENT DEFINITION
ospital admission Official admission to a hospital or other acute health care facility. Include dates of admission and discharge.
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Term Definition
radycardias
inus Node Function
inus arrhythmia Sinus arrhythmia characterized by the following:
● Normal P-wave morphology/axis
● Gradual phasic change in PP interval of more than 10% or 120 ms. Note that P-wave
morphology may change when sinus rate alters.
andering atrial pacemaker Atrial rhythm with at least 3 distinct P-wave morphologies at rates between 50 and 100 bpm
(cycle length between 1,200 and 600 ms).
inus bradycardia Sinus bradycardia characterized as sinus rate less than 60 beats per minute (bpm) (cycle length,
1000 msec) with normal P wave axis. Note that P wave morphology may be atypical at slow
rates.
inoatrial exit block Sinoatrial exit block characterized by the following:
Mobitz I:
● Normal P-wave morphology/axis
— Pauses with no visible sinus P waves
● Progressive decrease in PP interval before pause
● Constant PR interval
● PP interval of pause less than twice the PP interval preceding pause
● PP interval following pause greater than twice PP interval preceding pause
Mobitz II:
● Normal P-wave morphology/axis
— Pauses with no visible sinus P waves
● Constant PP interval before and after pause
● Pause is an integral multiple (within 100 ms) of normal PP interval
inus arrest/pause Pause without a P wave, 2.0 s during sinus rhythm; PP interval of pause not a multiple of basic
PP interval
inus node dysfunction (bradycardia) Sinus node dysfunction manifested as, for example:
● Sinus rate inappropriately slow for the conditions.
● Sinus arrest, sinoatrial exit block
● Prolonged pauses (analogous to sinus node recovery time 1,500 ms or a corrected sinus node
recovery time greater 550 ms) following cessation of supraventricular tachyarrhythmias.
ick sinus syndrome Sick sinus syndrome encompasses multiple supraventricular arrhythmias, which may include one or
more of the following: persistent, severe (50 bpm or less), or unexpected sinus bradycardia; sinus
pauses; failure of sinus rhythm to resume after cardioversion or spontaneous termination of
atrial tachyarrhythmias; sinoatrial exit block; bradycardia-tachycardia syndrome. Marked sinus
bradycardia may precipitate atrial fibrillation.
ctopic atrial rhythm An atrial rhythm arising from a site other than the sinus node with a rate between 60 and 100
bpm (cycle length 1,000 to 600 ms).Continued on next page
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Term Definition
trioventricular (AV) Conduction
hort PR interval PR interval 120 ms.
R prolongation (first-degree AV block) PR interval 200 ms.
econd-degree AV block Second-degree AV block characterized by the following:
● Mobitz I: progressive PR prolongation and shortening of RR interval until P wave is blocked.
Pause after blocked P wave is less than twice the PP interval. PR following block is shorter than
PR immediately preceding block.
● Mobitz II: regular sinus/atrial rhythm with intermittent nonconducted P waves. Constant PR
interval in the conducted beats.
dvanced or high-degree AV block Second-degree AV block often characterized by multiple, successive non-conducted P waves and
otherwise not consistent with Mobitz I or II that is ongoing or frequently recurring.
hird-degree AV block (complete
heart block)
Third-degree AV block is characterized by independent atrial and ventricular complexes with atrial
rate usually exceeding ventricular rate.
sorhythmic dissociation Independent atrial and ventricular rhythms at nearly identical rates. Junctional rhythm should be
excluded.
aroxysmal AV block Abrupt, prolonged temporary advanced AV block in the midst of otherwise normal AV
conduction (without change in PR interval), initiation of block by conducted or blocked atrial
premature depolarization, ventricular premature depolarization pause, or a change in sinus rate
(acceleration or deceleration). Resumption of conduction usually initiated by an escape impulse.
re-excitation An electrocardiogram (ECG) pattern characterized by a short PR interval, a widened QRS
complex, and a delta wave. A pre-excitation pattern on the ECG is evidence of the presence of
an anomalous AV connection, which results in ventricular activation prior to what would have
occurred through the normal His-Purkinje system. The PR interval is typically 120 ms.
elta wave Slurred (low dV/dt), early activation of the QRS complex seen as a manifestation of ventricular
pre-excitation. The delta wave is produced by AV conduction over an accessory pathway. The
QRS during sinus rhythm (usually more than 120 ms in duration) represents fusion of
ventricular depolarization over 2 or more conduction pathways—the accessory pathway(s) and
the normal conduction system. The size of the delta wave can vary, depending on how much of
the depolarization occurs over each pathway.
ntraventricular Conduction
eft anterior fascicular block Left anterior fascicular block is characterized by all of the following:
● Left-axis deviation with frontal QRS axis between 45° and 90°
● Q wave in lead aVL
● rS in inferior leads
● QRS duration is 120 ms
eft posterior fascicular block ● Right-axis deviation with frontal QRS axis between 90° and 180°
● rS in leads I and aVL and qR in inferior leads (Q waves 40 ms).
● QRS duration 120 ms
● Exclude other causes of right-axis deviation
eft bundle-branch block (LBBB) ● QRS duration 120 ms or longer
● Delayed onset of intrinsicoid deflection in 1, V5, and V6 60 ms
● Broad and notched or slurred R waves in I, aVL, V5, and V6
● rS or QS complexes in right precordial leads
● ST-segment and T waves in opposite polarity to the major QRS deflection
ight bundle branch block (RBBB) ● QRS duration 120 ms
● rsR= or rSR= complexes in V1 and V2
● Delayed onset of intrinsicoid deflection in V1 and V2 50 ms
● Broad, slurred S wave in 1, V5, and V6
● Secondary ST-T wave changes
ncomplete RBBB QRS morphology similar to RBBB with QRS duration 120 ms.
ntraventricular conduction delay,
nonspecific
QRS duration of 110 ms or more with morphology different from LBBB or RBBB.
achycardias
upraventricular Tachycardias
upraventricular tachycardia (SVT) An SVT is a tachycardia that emanates from or requires participation of supraventricular tissue. These
tachycardias can be either persistent or paroxysmal.
● Atrial tachycardias other than atrial fibrillation and flutter
● AV node re-entry
● AV re-entry
Note: The term PAT (paroxysmal atrial tachycardia) is no longer appropriate.
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Term Definition
trial premature complexes A depolarization of the atrium which occurs with a coupling interval shorter than that resulting
from the intrinsic heart rhythm.
trial tachycardia A usually regular cardiac arrhythmia arising from the atrium with a rate 100 bpm (cycle length
600 ms).
● Focal atrial tachycardias are characterized by usually regular atrial activation from atrial areas
with centrifugal spread, with rates usually between 100 to 250 bpm (rarely at 300 bpm). They
may arise from right or left atrial sites.
● Multifocal atrial tachycardia—an irregular tachycardia characterized by 3 or more different
P-wave morphologies at different rates, most commonly associated with underlying pulmonary
disease.
trial fibrillation (AF) A cardiac arrhythmia arising from the atrium with an atrial rate 300 bpm and an irregularly
irregular ventricular response in the presence of conduction. AF can be further characterized as:
● First detected AF
● Paroxysmal AF: AF is self-terminating within 7 days of recognized onset.
● Persistent AF: AF is not self-terminating within 7 days, or is terminated electrically or
pharmacologically.
● Permanent AF: cardioversion failed or not attempted.
acro–re-entrant atrial tachycardia A cardiac arrhythmia arising in the atrium which has a regular rate typically between 250 and 350
bpm (cycle length 240-170 ms) in the absence of antiarrhythmic drugs.
● Cavotricuspid isthmus (CTI)-dependent atrial flutter (also typical or type I atrial flutter): a re-
entrant tachycardia following a counterclockwise (typical) or clockwise (reverse typical) rotation
pattern around the tricuspid annulus resulting in a sawtooth pattern of atrial activation on
inferior ECG leads. This is amenable to curative catheter ablation of the CTI.
● Non-CTI dependent atrial flutter: macro–re-entrant tachycardias dependent upon an atrial scar
that creates conduction block and a central obstacle for re-entry. Prior cardiac surgery involving
the atrium is a common cause.
inus tachycardia (ST) A cardiac arrhythmia emanating from the sinus node at a rate 100 bpm (cycle length: 600 ms)
which demonstrates a gradual onset and termination and is in keeping with the level of
physical, emotional, pathological, or pharmacological stress.
nappropriate sinus tachycardia Increase in sinus rate unrelated to, or out of proportion with, the level of physical, emotional,
pathological, or pharmacological stress. Can be persistent or intermittent/paroxysmal.
ostural orthostatic tachycardia syndrome Orthostatic rise in heart rate of 30 bpm above baseline or 120 bpm within the first 10 min of
head-up tilt, accompanied by palpitations, and no significant (10 mm Hg) fall in systolic
blood pressure.
V node re-entry A regular SVT which results from re-entry within the AV node and/or perinodal atrial tissue.
Subclasses are:
● Slow-fast
● Fast-slow
● Slow-slow
unctional tachycardia A supraventricular arrhythmia that arises from the atrioventricular junction, has a rate 60 bpm
(cycle length: 1,000 ms), and may demonstrate dissociation from atrium or ventricle. Within
this category are discrete subsets with distinctly different natural histories:
● Congenital junctional ectopic tachycardia: observed exclusively in the pediatric population,
characterized by high heart rates and refractoriness to drug therapy. This condition may be
associated with high mortality if not diagnosed or if recognized late and not treated
appropriately.
● Postoperative junctional tachycardia: similar to congenital junctional ectopic tachycardia, but
observed in pediatric patients after cardiac surgery.
● Focal junctional tachycardia: a rare, highly symptomatic tachycardia found in young adults, often
exercise-related, with rates of 110 to 250 bpm. May cause tachycardia-related myopathy.
● Non-paroxysmal junctional tachycardia: a benign tachycardia with rates of 60 to 120 bpm and a
typical “warm-up” and “cool-down” pattern. It may indicate underlying conditions such as
digitalis toxicity.
● Other
V re-entrant tachycardia (AVRT) A re-entrant arrhythmia whose circuit involves the atrium, the AV node, the ventricles, and one
or more accessory AV connections. AVRT can be further classified as orthodromic AVRT, in
which conduction through the AP occurs from the ventricle to the atrium, or antedromic
AVRT, in which conduction through the AP occurs from the atrium to the ventricle.
olff-Parkinson-White syndrome Patients with tachycardia in association with ventricular pre-excitation.
Continued on next page
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Term Definition
entricular Tachycardias
entricular tachycardia (VT) VT is a cardiac arrhythmia of 3 or more consecutive complexes in duration emanating from the
ventricles at a rate 100 bpm (cycle length: 600 ms). Types of VT:
● Spontaneous: spontaneous occurrence of VT as assessed through electrocardiographic recording.
● Induced: VT induced through programmed ventricular stimulation, or delivery of external
energy, such as radiofrequency current.
● Sustained: VT 30 s in duration or requiring termination due to hemodynamic compromise in
30 s.
● Nonsustained/unsustained: 3 or more beats in duration, terminating spontaneously in 30 s.
● Bidirectional: VT with a beat-to-beat alternans in the QRS frontal plane axis, often associated
with digitalis toxicity.
● Exercise-induced: VT initiated through exercise.
● Narrow complex: A VT with a QRS duration is shorter than 120 ms.
T, monomorphic ● Sustained: VT with a stable single QRS morphology.
● Nonsustained/unsustained: nonsustained VT with a single QRS morphology.
● Repetitive: Paroxysmal and frequent (often incessant) nonsustained VT, usually in the absence of
structural heart disease, with a single morphology and normal intervening sinus beats.
T, polymorphic Types of polymorphic VT:
● Sustained: VT with a changing or multiform QRS morphology at cycle length 180 ms.
● Nonsustained/unsustained: nonsustained VT with a changing QRS morphology at cycle length
180 ms.
● Catecholaminergic: polymorphic VT associated with syncope and/or cardiac arrest triggered by
emotion or exercise in patients whose baseline ECG is normal.
remature ventricular complexes (PVC) A depolarization of the ventricle which occurs with a coupling interval shorter than that resulting
from the intrinsic heart rhythm.
entricular couplet Two consecutive PVCs separated by a maximum interval 600 ms.
ccelerated idioventricular rhythm Ectopic ventricular rhythm with 3 consecutive ventricular premature beats occurring at a rate
100 bpm (cycle length: 600 ms) but faster than the normal ventricular intrinsic escape rate
of 30 to 40 bpm (cycle length: 2,000 to 1,500 ms).
T storm History of VT storm as manifested by one of the following:
● Incessant VT, typically present in 50% of a 24-h period.
● A series of VT episodes triggering implantable cardioverter-defibrillator discharges within a short
time period (e.g., 20 discharges within 30 min).
denosine-sensitive VT VT responsive to adenosine therapy for termination.
erapamil-sensitive VT Idiopathic VT responsive to verapamil administration and may exhibit either RBBB or LBBB
morphology, though term usually applied to left ventricular septal tachycardias
entricular flutter A regular (cycle length variability 30 ms or less) ventricular arrhythmia approximately 300 bpm
(cycle length: 200 ms) with a monomorphic appearance; no isoelectric interval between
successive QRS complexes.
entricular fibrillation Rapid, usually more than 300 bpm (cycle length: 180 ms or less), grossly irregular ventricular
rhythm with marked variability in QRS cycle length, morphology, and amplitude.
orsades de pointes Patient has documented history of torsades de pointes as characterized by VT associated with a
long QT or QTc, and electrocardiographically characterized by twisting of the peaks of the
QRS complexes around the isoelectric line during the arrhythmia:
● Typical, initiated following “short-long-short” coupling intervals.
● Short coupled variant initiated by normal-short coupling.
entricular arrhythmias associated with
long QT syndrome
Polymorphic VT consistent with torsades de pointes.
● Congenital
● Acquired
— Heart block
— Medication
— Other
entricular arrhythmias associated with
Brugada syndrome
Polymorphic VT in the absence of structural heart disease and associated with a baseline ECG
pattern during sinus rhythm showing RBBB with ST segment elevation in leads V1 through
V3.
entricular arrhythmias associated with
short QT syndrome
Patient has documented history of ventricular arrhythmias associated with short QT syndrome as
characterized by one of the following:
● QTc 300 ms
● History of familial sudden death
● Short refractory periods
● Inducible ventricular fibrillation
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Term Definition
ascicular tachycardia A tachycardia that emanates from or requires participation of the distal fascicles (right or left
bundle branches).
undle branch reentrant tachycardia VT due to re-entry involving the His-Purkinje system, usually with LBBB morphology; this
usually occurs in the setting of cardiomyopathy.
diopathic RBBB VT VT in the absence of structural heart disease with RBBB morphology, typically responsive to
verapamil, also referred to as left ventricular septal tachycardia.
utflow tract VT Types of outflow tract VT:
● Right ventricular: focal VT emanating from the right ventricular outflow tract unrelated to
structural heart disease.
● Left ventricular: focal VT emanating from the left ventricular outflow tract unrelated to
structural heart disease.
PPENDIX B. Heart Rate Variability Time and Frequency Domain Units
Heart Rate Variability Time Domain Units
Time Domain Definition Unit
MSSD Root mean square of successive N-N interval difference ms
N 50 Number of pairs of adjacent NN intervals differing by more than 50 ms in the entire recording none
NN 50 NN50 count divided by the total number of all NN intervals %
DNN Standard deviation of all N-N intervals ms
DNN index The average of the standard deviations of N-N intervals for each 5 minutes of the entire recording ms
DANN Standard deviation of the 5-min average of N-N intervals of the entire recording ms
RV index Total number of all NN intervals divided by the height of the histogram of all NN intervals measured on a discrete
scale with bins of 7.8125 ms
none
DSD Standard deviation of differences between adjacent NN intervals ms
Heart Rate Frequency Domain Units
Frequency Domain* Definition Unit
otal power The energy in the heart period power spectrum up to 0.40 Hz ms2
ltra low-frequency (ULF) power The energy in the heart period power spectrum up to 0.0033 Hz ms2
ery low-frequency (VLF) power The energy in the heart period power spectrum between 0.0033 and 0.04 Hz ms2
ow-frequency (LF) power The energy in the heart period power spectrum between 0.04 and 0.15 Hz ms2
igh-frequency (HF) power The energy in the heart period power spectrum between 0.15 and 0.40 Hz ms2
F/HF ratio The ratio of low- to high-frequency power ms2
lpha Slow of log (power) on log (frequency) between 0.01 and 0.0001 Hz on a log-log plot ms2
Short-term recording: 5 min; entire recording: 24 h.
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